☰

Gary L. Johnson, Ph.D. - Publications

Affiliations: 
Pharmacology University of Colorado, Boulder, Boulder, CO, United States 
Website:
http://www.med.unc.edu/pharm/people/primaryfaculty/gary-l-johnson
Tree Info Similar researchers PubMed Report error

277/415 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Gomez SM, Drewry DH, Willson TM, Major MB, Townsend RR, Sorger PK, Johnson GL. Illuminating function of the understudied druggable kinome. Drug Discovery Today. 103881. PMID 38218213 DOI: 10.1016/j.drudis.2024.103881  0.367
2023 Joisa CU, Chen KA, Beville S, Stuhlmiller T, Berginski ME, Okumu D, Golitz BT, Johnson GL, Gomez SM. Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies. Biorxiv : the Preprint Server For Biology. PMID 37577663 DOI: 10.1101/2023.08.01.551346  0.306
2022 Asquith CRM, Temme L, East MP, Laitinen T, Pickett J, Kwarcinski FE, Sinha P, Wells CI, Johnson GL, Zutshi R, Drewry DH. Identification of 4-anilino-quin(az)oline as a cell active Protein Kinase Novel 3 (PKN3) inhibitor chemotype. Chemmedchem. PMID 35403825 DOI: 10.1002/cmdc.202200161  0.306
2021 East MP, Johnson GL. Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition. The Journal of Biological Chemistry. 101525. PMID 34958800 DOI: 10.1016/j.jbc.2021.101525  0.404
2020 Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL. Nf1 mutant tumors undergo transcriptome and kinome re-modeling after inhibition of either mTOR or MEK. Molecular Cancer Therapeutics. PMID 32847978 DOI: 10.1158/1535-7163.Mct-19-1017  0.357
2020 Goulet DR, Foster JP, Zawistowski JS, Bevill SM, Noel MP, Olivares-Quintero JF, Sciaky N, Singh D, Santos C, Pattenden SG, Davis IJ, Johnson GL. Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer. Molecular Cancer Research : McR. PMID 32753473 DOI: 10.1158/1541-7786.Mcr-19-1011  0.372
2020 Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Hollern DP, He X, Mott KR, Galván P, Fan C, Selitsky SR, Coffey AR, Marron D, Brasó-Maristany F, ... ... Johnson GL, et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. The Journal of Clinical Investigation. PMID 32573490 DOI: 10.1172/Jci130323  0.315
2020 Lipner MB, Peng XL, Jin C, Xu Y, Gao Y, East MP, Rashid NU, Moffitt RA, Herrera Loeza SG, Morrison AB, Golitz BT, Vaziri C, Graves LM, Johnson GL, Yeh JJ. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. Jci Insight. PMID 32213714 DOI: 10.1172/Jci.Insight.129905  0.427
2020 Yesilkanal AE, Yang D, Tiwari P, Sabino AU, Lee J, Xie X, Sun S, Dann C, Steinberg E, Stuhlmiller T, Frankenberger C, Goldsmith E, Johnson GL, Ramos AF, Rosner M. Abstract 5038: Limited inhibition of multiple nodes in a driver network blocks metastasis Cancer Research. 80: 5038-5038. DOI: 10.1158/1538-7445.Am2020-5038  0.407
2019 Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania B. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. Targeted Oncology. PMID 31429028 DOI: 10.1007/S11523-019-00662-4  0.331
2019 Wong JP, Stuhlmiller TJ, Giffin LC, Lin C, Bigi R, Zhao J, Zhang W, Bravo Cruz AG, Park SI, Earp HS, Dittmer DP, Frye SV, Wang X, Johnson GL, Damania B. Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 31346082 DOI: 10.1073/Pnas.1903991116  0.358
2019 Bevill SM, Olivares-Quintero JF, Sciaky N, Golitz BT, Singh D, Beltran AS, Rashid NU, Stuhlmiller TJ, Hale A, Moorman NJ, Santos CM, Angus SP, Zawistowski JS, Johnson GL. GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer. Molecular Cancer Research : McR. PMID 31000582 DOI: 10.1158/1541-7786.Mcr-18-1121  0.39
2019 Asquith CRM, Naegeli K, East M, Laitinen T, Havener T, Wells C, Johnson G, Drewry D, Zuercher W, Morris D. Design of a cyclin G associated kinase (GAK)/epidermal growth factor receptor (EGFR) inhibitor set to interrogate the relationship of EGFR and GAK in chordoma. Journal of Medicinal Chemistry. PMID 30973735 DOI: 10.1021/Acs.Jmedchem.9B00350  0.393
2019 Smithberger E, Shelton AK, Butler MK, Flores AR, Bash RE, Angus SP, Sciaky N, Dhruv HD, Johnson GL, Berens ME, Furnari FB, Miller CR. Abstract 3019: Dynamic kinome profiling of EGFRvIII-driven murine astrocyte models of glioblastoma reveals targets for dual kinase inhibitor therapy Cancer Research. 79: 3019-3019. DOI: 10.1158/1538-7445.Sabcs18-3019  0.461
2019 Shelton A, Smithberger E, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson GL, Berens ME, Furnari F, Miller CR. Abstract 331: Dynamic kinome targeting reveals kinases involved in acquired resistance to tyrosine kinase inhibitors in EGFR-driven glioblastomas Cancer Research. 79: 331-331. DOI: 10.1158/1538-7445.Am2019-331  0.39
2019 Smithberger E, Shelton A, Butler M, Flores A, Bash R, Angus S, East M, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Ryan Miller C. DRES-13. DUAL KINASE INHIBITION TO COMBAT EGFR-INHIBITOR RESISTANCE IN GLIOBLASTOMA Neuro-Oncology. 21: vi74-vi74. DOI: 10.1093/Neuonc/Noz175.300  0.483
2018 Gehlhausen JR, Hawley E, Wahle BM, He Y, Edwards D, Rhodes SD, Lajiness JD, Staser K, Chen S, Yang X, Yuan J, Li X, Jiang L, Smith A, Bessler W, ... ... Johnson GL, et al. A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas. Human Molecular Genetics. PMID 30335132 DOI: 10.1093/Hmg/Ddy361  0.386
2018 Krulikas LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, Yeh JJ, Johnson GL, et al. Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth. Slas Discovery : Advancing Life Sciences R & D. 2472555218773045. PMID 29742358 DOI: 10.1177/2472555218773045  0.325
2018 Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM. Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer. Oncotarget. 9: 15480-15497. PMID 29643987 DOI: 10.18632/Oncotarget.24337  0.435
2018 Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, ... ... Johnson GL, et al. Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers. Cancer Research. PMID 29472518 DOI: 10.1158/0008-5472.Can-17-1990  0.41
2018 Ahmad S, St Hilaire VR, Dandepally SR, Johnson GL, Williams AL, Scott JE. Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2). Biochemical and Biophysical Research Communications. PMID 29309787 DOI: 10.1016/J.Bbrc.2018.01.027  0.415
2018 Zawistowski J, Bevill S, Johnson GL. Abstract IA23: Enhancer remodeling in response to MEK inhibition in TNBC Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-Ia23  0.428
2018 Bevill SM, Sciaky N, Golitz BT, Rashid NU, Zawistowski JS, Johnson GL. Abstract B34: Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-B34  0.404
2018 Smithberger E, Flores AR, Butler MK, Dhruv HD, Johnson GL, Berens ME, Furnari FB, Miller CR. Abstract 2372: Kinome profiling of non-germline, genetically engineered mouse models of glioblastoma driven by Cdkn2a, Egfr, and/or Pten mutations reveals genotype-dependent kinase targets Cancer Research. 78: 2372-2372. DOI: 10.1158/1538-7445.Am2018-2372  0.44
2018 Matkar S, Sano R, Larmour C, Krytska K, Witek GM, Gerelus M, Stuhlmiller TJ, Johnson GL, Mosse YP. Abstract 1633: Chemical proteomics identifies druggable proteins in ALK-driven neuroblastomas Cancer Research. 78: 1633-1633. DOI: 10.1158/1538-7445.Am2018-1633  0.481
2018 Smithberger E, Shelton A, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Miller R. DRES-08. DYNAMIC KINOME PROFILING OF GENETICALLY-DEFINED, EGFRvIII-DRIVEN MURINE ASTROCYTE MODELS OF GLIOBLASTOMA REVEALS TARGETS FOR DUAL KINASE INHIBITOR THERAPY Neuro-Oncology. 20: vi77-vi77. DOI: 10.1093/Neuonc/Noy148.315  0.354
2018 Shelton A, Smithberger E, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Miller R. DRES-07. DEFINING THE MECHANISMS OF ACQUIRED RESISTANCE TO TYROSINE KINASE INHIBITORS IN EGFR-DRIVEN GLIOBLASTOMAS USING INTEGRATED KINOME AND TRANSCRIPTOME PROFILING Neuro-Oncology. 20: vi77-vi77. DOI: 10.1093/Neuonc/Noy148.314  0.392
2017 Bevill SM, Zawistowski JS, Johnson GL. Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer. Molecular & Cellular Oncology. 4: e1300622. PMID 29209639 DOI: 10.1080/23723556.2017.1300622  0.475
2017 Bevill SM, Zawistowski JS, Johnson GL. Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer. Molecular & Cellular Oncology. 4: e1300622. PMID 29209639 DOI: 10.1080/23723556.2017.1300622  0.372
2017 Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr D, Karagoz K, Sciaky N, Gatza M, Sharpless NE, Johnson GL, Bear JE. New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging. Cancer Research. PMID 29180473 DOI: 10.1158/0008-5472.Can-17-1653  0.343
2017 Cousins EM, Goldfarb D, Yan F, Roques J, Darr DB, Johnson GL, Major MB. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling. Molecular Cancer Research : McR. PMID 29133594 DOI: 10.1158/1541-7786.Mcr-17-0468  0.489
2017 Asquith CRM, Laitinen T, Bennett JM, Godoi PH, East MP, Tizzard GJ, Graves LM, Johnson GL, Dornsife RE, Wells CI, Elkins JM, Willson TM, Zuercher W. Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase. Chemmedchem. PMID 29072804 DOI: 10.1002/Cmdc.201700663  0.41
2017 Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, Johnson GL, Jensen BC. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition. Journal of the American Heart Association. 6. PMID 29051215 DOI: 10.1161/Jaha.117.006635  0.482
2017 Jensen BC, Parry TL, Huang W, Beak JY, Ilaiwy A, Bain JR, Newgard CB, Muehlbauer MJ, Patterson C, Johnson GL, Willis MS. Effects of the Kinase Inhibitor Sorafenib on Heart, Muscle, Liver, and Plasma Metabolism In Vivo using Non-Targeted Metabolomics Analysis. British Journal of Pharmacology. PMID 28977680 DOI: 10.1111/Bph.14062  0.45
2017 Angus SP, Zawistowski JS, Johnson GL. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. Annual Review of Pharmacology and Toxicology. PMID 28934561 DOI: 10.1146/Annurev-Pharmtox-010617-052954  0.423
2017 Jensen BC, Parry TL, Huang W, Ilaiwy A, Bain JR, Muehlbauer MJ, O'Neal SK, Patterson C, Johnson GL, Willis MS. Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo. Metabolites. 7. PMID 28640223 DOI: 10.3390/Metabo7030031  0.322
2017 Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, ... Johnson GL, et al. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro-Oncology. PMID 28486691 DOI: 10.1093/Neuonc/Nox052  0.413
2017 Cann ML, McDonald IM, East MP, Johnson GL, Graves LM. Measuring Kinase Activity - A Global Challenge. Journal of Cellular Biochemistry. PMID 28464261 DOI: 10.1002/Jcb.26103  0.484
2017 McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AE, ... ... Johnson GL, et al. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-Oncology. PMID 28379424 DOI: 10.1093/Neuonc/Nox044  0.477
2017 Mobley RJ, Raghu D, Duke LD, Abell-Hart K, Zawistowski JS, Lutz K, Gomez SM, Roy S, Homayouni R, Johnson GL, Abell AN. MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition. Cell Reports. 18: 2387-2400. PMID 28273454 DOI: 10.1016/J.Celrep.2017.02.030  0.39
2017 Arend KC, Lenarcic EM, Vincent HA, Rashid N, Lazear E, McDonald IM, Gilbert TS, East MP, Herring LE, Johnson GL, Graves L, Moorman NJ. Kinome Profiling Identifies Druggable Targets For Novel HCMV Antivirals. Molecular & Cellular Proteomics : McP. PMID 28237943 DOI: 10.1074/Mcp.M116.065375  0.434
2017 Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, ... ... Johnson GL, et al. Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex. Cancer Discovery. PMID 28108460 DOI: 10.1158/2159-8290.Cd-16-0653  0.401
2017 Angus SP, Stuhlmiller T, Sciaky N, Chen X, Naim R, Tanioka M, Gallagher KK, Forero A, Krop IE, Thompson AM, Murthy RK, He X, Perou CM, Earp S, Carey LA, ... Johnson GL, et al. TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa). Journal of Clinical Oncology. 35: 1027-1027. DOI: 10.1200/Jco.2017.35.15_Suppl.1027  0.337
2017 Velarde SH, Usary J, Perou C, Johnson GL. Abstract A30: Kinome dynamics in triple negative breast cancer in response to chemotherapy Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A30  0.335
2017 Swearingen AEDV, Sambade MJ, Siegel MB, Sud S, Bevill SM, Golitz BT, Bash RE, Santos CM, Darr DB, Parker JS, Miller CR, Johnson GL, Anders CK. Abstract A03: Several rational combination kinase inhibitor treatments identified by synthetic lethality screens are efficacious in intracranial triple negative breast cancer models Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A03  0.388
2016 Troutman S, Moleirinho S, Kota S, Nettles K, Fallahi M, Johnson GL, Kissil JL. Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1. Oncotarget. PMID 27363027 DOI: 10.18632/Oncotarget.10248  0.419
2016 Stuhlmiller TJ, Miller SM, Johnson GL. Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains. Molecular & Cellular Oncology. 3: e1052182. PMID 27308566 DOI: 10.1080/23723556.2015.1052182  0.416
2016 Miller SM, Goulet DR, Johnson GL. Targeting the breast cancer kinome. Journal of Cellular Physiology. PMID 27186656 DOI: 10.1002/Jcp.25427  0.416
2016 Bradford D, Whitcomb P, Dombi E, Chen AP, Baldwin A, Wolters P, Martin S, Glod J, Derdak J, Coyne GHO, Cowen EW, Holmblad M, Trepel J, Wood BJ, Paul SM, ... ... Johnson GL, et al. Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps2596  0.304
2016 Stuhlmiller TJ, Miller SM, Zawistowski JS, Duncan JS, Angus SP, Granger DA, Reuther RA, Collins KAL, Shawn GM, Kuan P, Chen X, Sciaky N, Johnson GL. Abstract B25: BET bromodomain inhibition targets adaptive responses to lapatinib in HER2-positive breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B25  0.502
2016 Zawistowski JS, Miller SM, Goulet DR, Stuhlmiller TJ, Singh D, Sciaky N, Velarde SH, Angus SP, Johnson GL. Abstract B24: Triple-negative breast cancer adaptive response to MEK inhibition is regulated by the induction of super-enhancers Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B24  0.455
2016 Miller SM, Zawistowski JS, Stuhlmiller TJ, Sciaky N, Santos CM, Darr DB, Johnson GL. Abstract B21: Suppression of adaptive resistance mechanisms to trametinib by inhibition of BET bromodomains in TNBC Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B21  0.499
2016 Yesilkanal AE, Frankenberger C, Rabe DC, Johnson GL, Rosner MR. Abstract 1620: Elucidating metastatic signaling networks in TNBC by investigating RKIP-regulated kinome Cancer Research. 76: 1620-1620. DOI: 10.1158/1538-7445.Tummet15-B23  0.48
2016 Wang X, Erdmann-Gilmore P, Viner R, Meyer M, Stuhlmiller T, Davies S, Li S, Zhang Q, Mooradian A, Huang K, Bomgarden R, Ding L, Ellis M, Rogers J, Johnson G, et al. Abstract LB-267: The proteomic landscape of patient-derived breast cancer xenografts reveals tumor-specific differences in the breast tumor microenvironment Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-267  0.343
2016 Swearingen AEDV, Sambade MJ, Sud S, Golitz B, Johnson GL, Anders CK. Abstract 3867: Combined PI3K and AURKA inhibition are efficacious in triple-negative breast cancer models Cancer Research. 76: 3867-3867. DOI: 10.1158/1538-7445.Am2016-3867  0.359
2015 Ahmad S, Johnson GL, Scott JE. Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity. Biochemical and Biophysical Research Communications. PMID 26056008 DOI: 10.1016/J.Bbrc.2015.06.029  0.431
2015 Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, ... ... Johnson GL, et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Reports. 11: 390-404. PMID 25865888 DOI: 10.1016/J.Celrep.2015.03.037  0.483
2015 Tignanelli CJ, Stratford J, Moffitt R, Reuther R, Johnson GL, Yeh JJ. Abstract B71: Multiplexed kinase inhibitor beads identify multiple pathways of resistance to PI3K inhibition facilitating the rational selection of novel combination therapies in pancreatic cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-B71  0.44
2015 Yesilkanal AE, Frankenberger C, Rabe D, Johnson GL, Rosner MR. Abstract 3251: Regulation of TNBC kinome by the metastasis suppressor Raf kinase inhibitory protein (RKIP) Cancer Research. 75: 3251-3251. DOI: 10.1158/1538-7445.Am2015-3251  0.459
2015 Swearingen AEDV, Siegel MB, Sambade MJ, Sud S, Miller SM, Silva G, Bash RE, Santos CM, Darr DB, Golitz B, Parker JS, Miller CR, Johnson GL, Anders CK. Abstract 2579: Combination therapy with MEK inhibition is efficacious in intracranial triple negative breast cancer models Cancer Research. 75: 2579-2579. DOI: 10.1158/1538-7445.Am2015-2579  0.376
2015 McNeill RS, Canoutas DA, Schmid RS, Bash RE, Constance BH, Azam SH, Reuther RA, Johnson GL, Miller CR. Atps-55Influence Of Mapk And Pi3K Pathway Mutations On Response To Targeted Inhibitors Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov204.55  0.404
2014 Stinchcombe TE, Johnson GL. MEK inhibition in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 86: 121-5. PMID 25257766 DOI: 10.1016/J.Lungcan.2014.09.005  0.346
2014 Zawistowski JS, Graves LM, Johnson GL. Assessing adaptation of the cancer kinome in response to targeted therapies. Biochemical Society Transactions. 42: 765-9. PMID 25109955 DOI: 10.1042/Bst20130274  0.497
2014 Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2516-22. PMID 24664307 DOI: 10.1158/1078-0432.Ccr-13-1081  0.503
2014 Turowec JP, Zukowski SA, Knight JD, Smalley DM, Graves LM, Johnson GL, Li SS, Lajoie GA, Litchfield DW. An unbiased proteomic screen reveals caspase cleavage is positively and negatively regulated by substrate phosphorylation. Molecular & Cellular Proteomics : McP. 13: 1184-97. PMID 24556848 DOI: 10.1074/Mcp.M113.037374  0.463
2014 Swearingen AEDV, Siegel MB, Bash R, Golitz B, Santos C, Darr D, Parker J, Johnson GL, Miller CR, Anders CK. Abstract 5449A: PI3K and MEK inhibition in intracranial triple negative breast cancer: Efficacy of BKM120 and AZD6244 in preclinical mouse models Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-5449A  0.321
2014 Angus SP, Stuhlmiller TJ, Reuther R, Pham TT, Granger DA, Darr DB, Jordan JL, Moschos SJ, Johnson GL, Sharpless NE. Abstract 4761: Defining the adaptive kinome response to BRAF and MEK inhibition in melanoma Cancer Research. 74: 4761-4761. DOI: 10.1158/1538-7445.Am2014-4761  0.475
2014 Liu J, Yang C, Simpson C, DeRyckere D, Deusen AV, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, et al. Correction to Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia Acs Medicinal Chemistry Letters. 5: 1173-1173. DOI: 10.1021/Ml500328M  0.364
2013 Pham TT, Angus SP, Johnson GL. MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis. Genes & Cancer. 4: 419-26. PMID 24386504 DOI: 10.1177/1947601913513950  0.511
2013 Wu C, Haynes EM, Asokan SB, Simon JM, Sharpless NE, Baldwin AS, Davis IJ, Johnson GL, Bear JE. Loss of Arp2/3 induces an NF-κB-dependent, nonautonomous effect on chemotactic signaling. The Journal of Cell Biology. 203: 907-16. PMID 24344184 DOI: 10.1083/Jcb.201306032  0.366
2013 Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, ... ... Johnson GL, et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics. 12: 2367-77. PMID 23997116 DOI: 10.1158/1535-7163.Mct-13-0040  0.404
2013 Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, ... Johnson GL, et al. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. Plos One. 8: e66755. PMID 23826126 DOI: 10.1371/Journal.Pone.0066755  0.5
2013 Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Molecular and Cellular Biology. 33: 3011-25. PMID 23716599 DOI: 10.1128/Mcb.01443-12  0.344
2013 Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, Johnson GL. MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Molecular and Cellular Biology. 33: 2260-74. PMID 23530058 DOI: 10.1128/Mcb.00269-13  0.328
2013 Dillon PJ, Gregory SM, Tamburro K, Sanders MK, Johnson GL, Raab-Traub N, Dittmer DP, Damania B. Tousled-like kinases modulate reactivation of gammaherpesviruses from latency. Cell Host & Microbe. 13: 204-14. PMID 23414760 DOI: 10.1016/J.Chom.2012.12.005  0.37
2013 Graves LM, Duncan JS, Whittle MC, Johnson GL. The dynamic nature of the kinome. The Biochemical Journal. 450: 1-8. PMID 23343193 DOI: 10.1042/Bj20121456  0.446
2013 Ahmad S, Hughes MA, Johnson GL, Scott JE. Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors. Journal of Biomolecular Screening. 18: 388-99. PMID 23134735 DOI: 10.1177/1087057112466430  0.376
2013 Richardson BT, Dibble CF, Borikova AL, Johnson GL. Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling. Biological Chemistry. 394: 35-42. PMID 23096573 DOI: 10.1515/Hsz-2012-0243  0.384
2013 Johnson GL, Amos KD, Duncan JS, Whittle M, Zawistowki J, Goulet D, He X, Noe J, Perou CM, Earp S, Carey LA. Kinome reprogramming response to MEK inhibition: A window-of-opportunity trial in triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 31: 512-512. DOI: 10.1200/Jco.2013.31.15_Suppl.512  0.415
2013 Johnson G. Abstract SY10-02: Breast cancer subtypes have selective kinome reprogramming in response to kinase inhibitors. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy10-02  0.389
2012 Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5290-303. PMID 22872574 DOI: 10.1158/1078-0432.Ccr-12-0563  0.404
2012 Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, et al. Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. Acs Medicinal Chemistry Letters. 3: 129-134. PMID 22662287 DOI: 10.1021/Ml200239K  0.446
2012 Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, ... ... Johnson GL, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 149: 307-21. PMID 22500798 DOI: 10.1016/J.Cell.2012.02.053  0.466
2012 Midland AA, Whittle MC, Duncan JS, Abell AN, Nakamura K, Zawistowski JS, Carey LA, Earp HS, Graves LM, Gomez SM, Johnson GL. Defining the expressed breast cancer kinome. Cell Research. 22: 620-3. PMID 22310242 DOI: 10.1038/Cr.2012.25  0.428
2012 Cronan MR, Nakamura K, Johnson NL, Granger DA, Cuevas BD, Wang JG, Mackman N, Scott JE, Dohlman HG, Johnson GL. Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis. Oncogene. 31: 3889-900. PMID 22139075 DOI: 10.1038/Onc.2011.544  0.462
2012 Christoph S, DeRyckere D, Schlegel J, Sather S, McGranahan A, Franzer JK, Trakhimets A, Wang X, Kireev D, Janzen W, Liu J, Yang C, Simpson C, Norris-Drouin J, Frye S, ... ... Johnson GL, et al. Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo. Blood. 120: 2607-2607. DOI: 10.1182/Blood.V120.21.2607.2607  0.361
2012 Whittle MC, Duncan JS, Graves LM, Johnson GL. Abstract B37: Monitoring kinome response to EGFR inhibition in triple negative breast cancer Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-B37  0.416
2012 Duncan JS, Whittle MW, Graves LM, Johnson GL. Abstract B23: Reprogramming of the cancer kinome in response to targeted kinase inhibition Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-B23  0.48
2011 Abell AN, Jordan NV, Huang W, Prat A, Midland AA, Johnson NL, Granger DA, Mieczkowski PA, Perou CM, Gomez SM, Li L, Johnson GL. MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell. 8: 525-37. PMID 21549327 DOI: 10.1016/J.Stem.2011.03.008  0.363
2011 Johnson GL. Defining MAPK interactomes. Acs Chemical Biology. 6: 18-20. PMID 21128644 DOI: 10.1021/Cb100384Z  0.416
2011 Darzynkiewicz Z, Pozarowski P, Lee BW, Johnson GL. Fluorochrome-labeled inhibitors of caspases: convenient in vitro and in vivo markers of apoptotic cells for cytometric analysis. Methods in Molecular Biology (Clifton, N.J.). 682: 103-14. PMID 21057924 DOI: 10.1007/978-1-60327-409-8_9  0.314
2011 Christoph S, DeRyckere D, Sather S, Wang X, Kireev D, Janzen W, Liu J, Yang C, van Deusen A, Simpson C, Norris-Drouin J, Frye S, Earp HS, Johnson GL, Graham DK. UNC569 As Novel Small Molecule Mer Receptor Tyrosine Kinase Inhibitor for Treatment of ALL Blood. 118: 2589-2589. DOI: 10.1182/Blood.V118.21.2589.2589  0.44
2010 Nakamura K, Johnson GL. Activity assays for extracellular signal-regulated kinase 5. Methods in Molecular Biology (Clifton, N.J.). 661: 91-106. PMID 20811978 DOI: 10.1007/978-1-60761-795-2_5  0.547
2010 Konhilas JP, Boucek DM, Horn TR, Johnson GL, Leinwand LA. The role of MEKK1 in hypertrophic cardiomyopathy. International Heart Journal. 51: 277-84. PMID 20716846 DOI: 10.1536/Ihj.51.277  0.342
2010 Dibble CF, Horst JA, Malone MH, Park K, Temple B, Cheeseman H, Barbaro JR, Johnson GL, Bencharit S. Defining the functional domain of programmed cell death 10 through its interactions with phosphatidylinositol-3,4,5-trisphosphate. Plos One. 5: e11740. PMID 20668527 DOI: 10.1371/Journal.Pone.0011740  0.331
2010 Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, Johnson GL. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. The Journal of Biological Chemistry. 285: 11760-4. PMID 20181950 DOI: 10.1074/Jbc.C109.097220  0.475
2010 Nakamura K, Kimple AJ, Siderovski DP, Johnson GL. PB1 domain interaction of p62/sequestosome 1 and MEKK3 regulates NF-kappaB activation. The Journal of Biological Chemistry. 285: 2077-89. PMID 19903815 DOI: 10.1074/Jbc.M109.065102  0.352
2009 Machacek M, Hodgson L, Welch C, Elliott H, Pertz O, Nalbant P, Abell A, Johnson GL, Hahn KM, Danuser G. Coordination of Rho GTPase activities during cell protrusion. Nature. 461: 99-103. PMID 19693013 DOI: 10.1038/Nature08242  0.416
2009 Johnson GL, Gomez SM. Sequence patches on MAPK surfaces define protein-protein interactions. Genome Biology. 10: 222. PMID 19519955 DOI: 10.1186/Gb-2009-10-6-222  0.381
2009 Frye SV, Johnson GL. Inhibitors paradoxically prime kinases. Nature Chemical Biology. 5: 448-9. PMID 19465930 DOI: 10.1038/Nchembio.F.11  0.462
2009 Crose LE, Hilder TL, Sciaky N, Johnson GL. Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. The Journal of Biological Chemistry. 284: 13301-5. PMID 19318350 DOI: 10.1074/Jbc.C900009200  0.337
2009 Abell AN, Granger DA, Johnson NL, Vincent-Jordan N, Dibble CF, Johnson GL. Trophoblast stem cell maintenance by fibroblast growth factor 4 requires MEKK4 activation of Jun N-terminal kinase. Molecular and Cellular Biology. 29: 2748-61. PMID 19289495 DOI: 10.1128/Mcb.01391-08  0.517
2009 Xie L, Jing L, Yu Y, Nakamura K, Parker CE, Johnson GL, Chen X. In vivo profiling endogenous interactions with knock-out in mammalian cells. Analytical Chemistry. 81: 1411-7. PMID 19199569 DOI: 10.1021/Ac802161D  0.374
2008 Wu Y, Johnson GL, Gomez SM. Data-driven modeling of cellular stimulation, signaling and output response in RAW 264.7 cells. Journal of Molecular Signaling. 3: 11. PMID 18498628 DOI: 10.1186/1750-2187-3-11  0.33
2008 Nakamura K, Zawistowski JS, Hughes MA, Sexton JZ, Yeh LA, Johnson GL, Scott JE. Homogeneous time-resolved fluorescence resonance energy transfer assay for measurement of Phox/Bem1p (PB1) domain heterodimerization. Journal of Biomolecular Screening. 13: 396-405. PMID 18480472 DOI: 10.1177/1087057108318281  0.389
2008 Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 27: 4434-45. PMID 18372913 DOI: 10.1038/Onc.2008.84  0.356
2008 Mendoza H, Campbell DG, Burness K, Hastie J, Ronkina N, Shim JH, Arthur JS, Davis RJ, Gaestel M, Johnson GL, Ghosh S, Cohen P. Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. The Biochemical Journal. 409: 711-22. PMID 18021073 DOI: 10.1042/Bj20071149  0.519
2008 Stalheim L, Johnson GL. MAPK kinase kinase regulation of SAPK/JNK pathways Topics in Current Genetics. 20: 1-15. DOI: 10.1007/4735_2007_0238  0.39
2007 Hilder TL, Malone MH, Bencharit S, Colicelli J, Haystead TA, Johnson GL, Wu CC. Proteomic identification of the cerebral cavernous malformation signaling complex. Journal of Proteome Research. 6: 4343-55. PMID 17900104 DOI: 10.1021/Pr0704276  0.37
2007 Hilder TL, Malone MH, Johnson GL. Hyperosmotic induction of mitogen-activated protein kinase scaffolding. Methods in Enzymology. 428: 297-312. PMID 17875425 DOI: 10.1016/S0076-6879(07)28017-6  0.509
2007 Winter-Vann AM, Johnson GL. Integrated activation of MAP3Ks balances cell fate in response to stress. Journal of Cellular Biochemistry. 102: 848-58. PMID 17786929 DOI: 10.1002/Jcb.21522  0.465
2007 Abell AN, Granger DA, Johnson GL. MEKK4 stimulation of p38 and JNK activity is negatively regulated by GSK3beta. The Journal of Biological Chemistry. 282: 30476-84. PMID 17726008 DOI: 10.1074/Jbc.M705783200  0.512
2007 Cuevas BD, Abell AN, Johnson GL. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene. 26: 3159-71. PMID 17496913 DOI: 10.1038/Sj.Onc.1210409  0.562
2007 Dhanasekaran DN, Johnson GL. MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene. 26: 3097-9. PMID 17496908 DOI: 10.1038/Sj.Onc.1210395  0.303
2007 Nakamura K, Johnson GL. Noncanonical function of MEKK2 and MEK5 PB1 domains for coordinated extracellular signal-regulated kinase 5 and c-Jun N-terminal kinase signaling. Molecular and Cellular Biology. 27: 4566-77. PMID 17452462 DOI: 10.1128/Mcb.00125-07  0.424
2007 Johnson GL, Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochimica Et Biophysica Acta. 1773: 1341-8. PMID 17306896 DOI: 10.1016/J.Bbamcr.2006.12.009  0.448
2007 Xia Y, Wang J, Xu S, Johnson GL, Hunter T, Lu Z. MEKK1 mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. Molecular and Cellular Biology. 27: 510-7. PMID 17101801 DOI: 10.1128/Mcb.01355-06  0.364
2007 Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, Blancafort P. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene. 26: 2791-8. PMID 17057734 DOI: 10.1038/Sj.Onc.1210072  0.338
2006 Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, Deryckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, ... Johnson GL, et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene. 25: 6092-100. PMID 16652142 DOI: 10.1038/Sj.Onc.1209633  0.406
2006 Cuevas BD, Winter-Vann AM, Johnson NL, Johnson GL. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Oncogene. 25: 4998-5010. PMID 16568086 DOI: 10.1038/Sj.Onc.1209507  0.378
2006 Nakamura K, Uhlik MT, Johnson NL, Hahn KM, Johnson GL. PB1 domain-dependent signaling complex is required for extracellular signal-regulated kinase 5 activation. Molecular and Cellular Biology. 26: 2065-79. PMID 16507987 DOI: 10.1128/Mcb.26.6.2065-2079.2006  0.46
2005 Lapadat R, Debiasi RL, Johnson GL, Tyler KL, Shah I. Genes Induced by Reovirus Infection Have a Distinct Modular Cis-Regulatory Architecture. Current Genomics. 6: 501-513. PMID 23335855 DOI: 10.2174/138920205775067675  0.316
2005 Abell AN, Rivera-Perez JA, Cuevas BD, Uhlik MT, Sather S, Johnson NL, Minton SK, Lauder JM, Winter-Vann AM, Nakamura K, Magnuson T, Vaillancourt RR, Heasley LE, Johnson GL. Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo. Molecular and Cellular Biology. 25: 8948-59. PMID 16199873 DOI: 10.1128/Mcb.25.20.8948-8959.2005  0.709
2005 Abell AN, Johnson GL. MEKK4 is an effector of the embryonic TRAF4 for JNK activation. The Journal of Biological Chemistry. 280: 35793-6. PMID 16157600 DOI: 10.1074/Jbc.C500260200  0.537
2005 Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL, Marchuk DA. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Human Molecular Genetics. 14: 2521-31. PMID 16037064 DOI: 10.1093/Hmg/Ddi256  0.324
2005 Johnson GL, Dohlman HG, Graves LM. MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. Current Opinion in Chemical Biology. 9: 325-31. PMID 15939336 DOI: 10.1016/J.Cbpa.2005.04.004  0.539
2005 Li Y, Minamino T, Tsukamoto O, Yujiri T, Shintani Y, Okada K, Nagamachi Y, Fujita M, Hirata A, Sanada S, Asanuma H, Takashima S, Hori M, Johnson GL, Kitakaze M. Ablation of MEK kinase 1 suppresses intimal hyperplasia by impairing smooth muscle cell migration and urokinase plasminogen activator expression in a mouse blood-flow cessation model. Circulation. 111: 1672-8. PMID 15795331 DOI: 10.1161/01.Cir.0000160350.20810.0F  0.344
2005 Huang X, Lee B, Johnson G, Naleway J, Guzikowski A, Dai W, Darzynkiewicz Z. Novel assay utilizing fluorochrome-tagged physostigmine (Ph-F) to in situ detect active acetylcholinesterase (AChE) induced during apoptosis Cell Cycle. 4: 140-147. PMID 15611638 DOI: 10.4161/Cc.4.1.1322  0.312
2005 Uhlik MT, Temple B, Bencharit S, Kimple AJ, Siderovski DP, Johnson GL. Structural and evolutionary division of phosphotyrosine binding (PTB) domains. Journal of Molecular Biology. 345: 1-20. PMID 15567406 DOI: 10.1016/J.Jmb.2004.10.038  0.313
2005 Cuevas BD, Uhlik MT, Garrington TP, Johnson GL. MEKK1 regulates the AP-1 dimer repertoire via control of JunB transcription and Fra-2 protein stability. Oncogene. 24: 801-9. PMID 15558021 DOI: 10.1038/Sj.Onc.1208239  0.5
2004 Uhlik MT, Abell AN, Cuevas BD, Nakamura K, Johnson GL. Wiring diagrams of MAPK regulation by MEKK1, 2, and 3. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 82: 658-63. PMID 15674433 DOI: 10.1139/O04-114  0.516
2004 Clarke P, Meintzer SM, Wang Y, Moffitt LA, Richardson-Burns SM, Johnson GL, Tyler KL. JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells. Journal of Virology. 78: 13132-8. PMID 15542665 DOI: 10.1128/Jvi.78.23.13132-13138.2004  0.436
2004 Anderson MS, Knall C, Thurman G, Mann D, Cusack N, Johnson GL, Ambruso DR. CP-64131, an aminobenzazepine with cytokine-like properties, stimulates human neutrophil functions through the p38-MAPK pathway. Journal of Leukocyte Biology. 76: 477-83. PMID 15155776 DOI: 10.1189/Jlb.0903422  0.47
2004 Kesavan K, Lobel-Rice K, Sun W, Lapadat R, Webb S, Johnson GL, Garrington TP. MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts. Journal of Cellular Physiology. 199: 140-8. PMID 14978743 DOI: 10.1002/Jcp.10457  0.809
2004 Abell AN, DeCathelineau AM, Weed SA, Ambruso DR, Riches DW, Johnson GL. Rac2D57N, a dominant inhibitory Rac2 mutant that inhibits p38 kinase signaling and prevents surface ruffling in bone-marrow-derived macrophages. Journal of Cell Science. 117: 243-55. PMID 14676277 DOI: 10.1242/Jcs.00853  0.454
2004 Pozarowski P, Huang X, Halicka DH, Lee B, Johnson G, Darzynkiewicz Z. Interactions of fluorochrome-labeled caspase inhibitors with apoptotic cells: a caution in data interpretation. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 55: 50-60. PMID 12938188 DOI: 10.1002/Cyto.A.10074  0.335
2003 Uhlik MT, Abell AN, Johnson NL, Sun W, Cuevas BD, Lobel-Rice KE, Horne EA, Dell'Acqua ML, Johnson GL. Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nature Cell Biology. 5: 1104-10. PMID 14634666 DOI: 10.1038/Ncb1071  0.782
2003 Wei X, Sun W, Fan R, Hahn J, Joetham A, Li G, Webb S, Garrington T, Dakhama A, Lucas J, Johnson GL, Gelfand EW. MEF2C regulates c-Jun but not TNF-alpha gene expression in stimulated mast cells. European Journal of Immunology. 33: 2903-9. PMID 14515274 DOI: 10.1002/Eji.200324127  0.551
2003 Nakamura K, Johnson GL. PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway. The Journal of Biological Chemistry. 278: 36989-92. PMID 12912994 DOI: 10.1074/Jbc.C300313200  0.442
2003 DeBiasi RL, Clarke P, Meintzer S, Jotte R, Kleinschmidt-Demasters BK, Johnson GL, Tyler KL. Reovirus-induced alteration in expression of apoptosis and DNA repair genes with potential roles in viral pathogenesis. Journal of Virology. 77: 8934-47. PMID 12885910 DOI: 10.1128/Jvi.77.16.8934-8947.2003  0.32
2003 Cuevas BD, Abell AN, Witowsky JA, Yujiri T, Johnson NL, Kesavan K, Ware M, Jones PL, Weed SA, DeBiasi RL, Oka Y, Tyler KL, Johnson GL. MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts. The Embo Journal. 22: 3346-55. PMID 12839996 DOI: 10.1093/Emboj/Cdg322  0.81
2003 Sun W, Wei X, Kesavan K, Garrington TP, Fan R, Mei J, Anderson SM, Gelfand EW, Johnson GL. MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src. Molecular and Cellular Biology. 23: 2298-308. PMID 12640115 DOI: 10.1128/Mcb.23.7.2298-2308.2003  0.573
2003 Witowsky J, Abell A, Johnson NL, Johnson GL, Cuevas BD. MEKK1 is required for inducible urokinase-type plasminogen activator expression. The Journal of Biological Chemistry. 278: 5941-6. PMID 12493778 DOI: 10.1074/Jbc.M212363200  0.815
2003 Witowsky JA, Johnson GL. Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways. The Journal of Biological Chemistry. 278: 1403-6. PMID 12456688 DOI: 10.1074/Jbc.C200616200  0.827
2002 Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (New York, N.Y.). 298: 1911-2. PMID 12471242 DOI: 10.1126/Science.1072682  0.541
2002 Grabarek J, Du L, Johnson GL, Lee BW, Phelps DJ, Darzynkiewicz Z. Sequential activation of caspases and serine proteases (serpases) during apoptosis. Cell Cycle (Georgetown, Tex.). 1: 124-31. PMID 12429921 DOI: 10.4161/Cc.1.2.113  0.373
2002 Bild AH, Mendoza FJ, Gibson EM, Huang M, Villanueva J, Garrington TP, Jove R, Johnson GL, Gibson SB. MEKK1-induced apoptosis requires TRAIL death receptor activation and is inhibited by AKT/PKB through inhibition of MEKK1 cleavage. Oncogene. 21: 6649-56. PMID 12242663 DOI: 10.1038/Sj.Onc.1205819  0.679
2002 Gallo KA, Johnson GL. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nature Reviews. Molecular Cell Biology. 3: 663-72. PMID 12209126 DOI: 10.1038/Nrm906  0.521
2002 Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, Liu J, Takagi G, Karoor V, Hong C, Johnson GL, Vatner DE, Vatner SF. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. The Journal of Clinical Investigation. 110: 271-9. PMID 12122119 DOI: 10.1172/Jci14938  0.375
2002 Darzynkiewicz Z, Bedner E, Smolewski P, Lee BW, Johnson GL. Detection of caspases activation in situ by fluorochrome-labeled inhibitors of caspases (FLICA). Methods in Molecular Biology (Clifton, N.J.). 203: 289-99. PMID 12073450 DOI: 10.1385/1-59259-179-5:289  0.32
2002 Kassenbrock CK, Hunter S, Garl P, Johnson GL, Anderson SM. Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor. The Journal of Biological Chemistry. 277: 24967-75. PMID 11994282 DOI: 10.1074/Jbc.M201026200  0.532
2002 Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, Baron A, Yang J, Puck T, Bunn P. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism Proceedings of the National Academy of Sciences of the United States of America. 99: 4608-4613. PMID 11930011 DOI: 10.1073/Pnas.072077299  0.389
2002 Smolewski P, Grabarek J, Lee BW, Johnson GL, Darzynkiewicz Z. Kinetics of HL-60 cell entry to apoptosis during treatment with TNF-alpha or camptothecin assayed by the stathmo-apoptosis method. Cytometry. 47: 143-9. PMID 11891718 DOI: 10.1002/Cyto.10062  0.337
2002 Minamino T, Yujiri T, Terada N, Taffet GE, Michael LH, Johnson GL, Schneider MD. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proceedings of the National Academy of Sciences of the United States of America. 99: 3866-71. PMID 11891332 DOI: 10.1073/Pnas.062453699  0.392
2002 Poggioli GJ, DeBiasi RL, Bickel R, Jotte R, Spalding A, Johnson GL, Tyler KL. Reovirus-induced alterations in gene expression related to cell cycle regulation. Journal of Virology. 76: 2585-94. PMID 11861824 DOI: 10.1128/Jvi.76.6.2585-2594.2002  0.701
2002 Johnson G. Scaffolding proteins - More than meets the eye Science. 295: 1249-1250. PMID 11847330 DOI: 10.1126/Science.1069828  0.42
2002 Spalding AC, Jotte RM, Scheinman RI, Geraci MW, Clarke P, Tyler KL, Johnson GL. TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene. 21: 260-71. PMID 11803469 DOI: 10.1038/Sj.Onc.1205048  0.702
2002 Schlesinger TK, Bonvin C, Jarpe MB, Fanger GR, Cardinaux JR, Johnson GL, Widmann C. Apoptosis stimulated by the 91-kDa caspase cleavage MEKK1 fragment requires translocation to soluble cellular compartments. The Journal of Biological Chemistry. 277: 10283-91. PMID 11782455 DOI: 10.1074/Jbc.M106885200  0.49
2002 Bonvin C, Guillon A, van Bemmelen MX, Gerwins P, Johnson GL, Widmann C. Role of the amino-terminal domains of MEKKs in the activation of NF kappa B and MAPK pathways and in the regulation of cell proliferation and apoptosis. Cellular Signalling. 14: 123-31. PMID 11781136 DOI: 10.1016/S0898-6568(01)00219-4  0.521
2002 Wei X, Wei R, Garrington T, Johnson GL, Gelfand EW. MEKK2-MEK5-BMK1/ERK5-MEF2C activation: A new pathway regulating c-jun gene expression in stimulated mast cells The Journal of Allergy and Clinical Immunology. 109. DOI: 10.1016/S0091-6749(02)82133-9  0.432
2001 Clarke P, Meintzer SM, Widmann C, Johnson GL, Tyler KL. Reovirus infection activates JNK and the JNK-dependent transcription factor c-Jun Journal of Virology. 75: 11275-11283. PMID 11689607 DOI: 10.1128/Jvi.75.23.11275-11283.2001  0.496
2001 Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene. 20: 6910-9. PMID 11687970 DOI: 10.1038/Sj.Onc.1204842  0.654
2001 Amstad PA, Yu G, Johnson GL, Lee BW, Dhawan S, Phelps DJ. Detection of caspase activation in situ by fluorochrome-labeled caspase inhibitors. Biotechniques. 31: 608-616. PMID 11570504 DOI: 10.2144/01313Pf01  0.313
2001 Widmann C, Sather S, Oyer R, Johnson GL, Dreskin SC. In vitro activity of MEKK2 and MEKK3 in detergents is a function of a valine to serine difference in the catalytic domain Biochimica Et Biophysica Acta - Protein Structure and Molecular Enzymology. 1547: 167-173. PMID 11343802 DOI: 10.1016/S0167-4838(01)00183-2  0.5
2001 Chayama K, Papst PJ, Garrington TP, Pratt JC, Ishizuka T, Webb S, Ganiatsas S, Zon LI, Sun W, Johnson GL, Gelfand EW. Role of MEKK2-MEK5 in the regulation of TNF-alpha gene expression and MEKK2-MKK7 in the activation of c-Jun N-terminal kinase in mast cells. Proceedings of the National Academy of Sciences of the United States of America. 98: 4599-604. PMID 11274363 DOI: 10.1073/Pnas.081021898  0.55
2001 Sun W, Kesavan K, Schaefer BC, Garrington TP, Ware M, Johnson NL, Gelfand EW, Johnson GL. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. Journal of Biological Chemistry. 276: 5093-5100. PMID 11073940 DOI: 10.1074/Jbc.M003719200  0.552
2000 Avdi NJ, Nick JA, Whitlock BB, Billstrom MA, Henson PM, Johnson GL, Worthen GS. Tumor necrosis factor-alpha activation of the c-Jun N-terminal kinase pathway in human neutrophils. Integrin involvement in a pathway leading from cytoplasmic tyrosine kinases apoptosis. The Journal of Biological Chemistry. 276: 2189-99. PMID 11053415 DOI: 10.1074/Jbc.M007527200  0.498
2000 Garrington TP, Ishizuka T, Papst PJ, Chayama K, Webb S, Yujiri T, Sun W, Sather S, Russell DM, Gibson SB, Keller G, Gelfand EW, Johnson GL. MEKK2 gene disruption causes loss of cytokine production in response to IgE and c-Kit ligand stimulation of ES cell-derived mast cells. The Embo Journal. 19: 5387-95. PMID 11032806 DOI: 10.1093/Emboj/19.20.5387  0.495
2000 Clarke P, Meintzer SM, Gibson S, Widmann C, Garrington TP, Johnson GL, Tyler KL. Reovirus-induced apoptosis is mediated by TRAIL Journal of Virology. 74: 8135-8139. PMID 10933724 DOI: 10.1128/Jvi.74.17.8135-8139.2000  0.341
2000 Kharbanda S, Pandey P, Yamauchi T, Kumar S, Kaneki M, Kumar V, Bharti A, Yuan ZM, Ghanem L, Rana A, Weichselbaum R, Johnson G, Kufe D. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Molecular and Cellular Biology. 20: 4979-89. PMID 10866655 DOI: 10.1128/Mcb.20.14.4979-4989.2000  0.477
2000 Yujiri T, Ware M, Widmann C, Oyer R, Russell D, Chan E, Zaitsu Y, Clarke P, Tyler K, Oka Y, Fanger GR, Henson P, Johnson GL. MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation Proceedings of the National Academy of Sciences of the United States of America. 97: 7272-7277. PMID 10852963 DOI: 10.1073/Pnas.130176697  0.538
2000 Sakata N, Hamelmann E, Siadak AW, Terada N, Gerwins P, Aruffo A, Johnson GL, Gelfand EW. Differential regulation of CD40-mediated human B cell responses by antibodies directed against different CD40 epitopes. Cellular Immunology. 201: 109-123. PMID 10831320 DOI: 10.1006/Cimm.2000.1645  0.379
2000 Sun W, Vincent S, Settleman J, Johnson GL. MEK kinase 2 binds and activates protein kinase C-related kinase 2. Bifurcation of kinase regulatory pathways at the level of an MAPK kinase kinase. Journal of Biological Chemistry. 275: 24421-24428. PMID 10818102 DOI: 10.1074/Jbc.M003148200  0.515
2000 Ambruso DR, Knall C, Abell AN, Panepinto J, Kurkchubasche A, Thurman G, Gonzalez-Aller C, Hiester A, DeBoer M, Harbeck RJ, Oyer R, Johnson GL, Roos D. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation Proceedings of the National Academy of Sciences of the United States of America. 97: 4654-4659. PMID 10758162 DOI: 10.1073/Pnas.080074897  0.308
2000 Sakata N, Kawasome H, Terada N, Johnson GL, Gelfand EW. CD40 and adenosine A2 receptor agonist-cyclic adenosine monophosphate rescue B-cell antigen receptor-induced apoptosis through independent pathways and converge to prevent caspase activation The Journal of Allergy and Clinical Immunology. 105: 522-531. PMID 10719303 DOI: 10.1067/Mai.2000.104251  0.383
2000 Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Molecular and Cellular Biology. 20: 205-12. PMID 10594023 DOI: 10.1128/Mcb.20.1.205-212.2000  0.716
1999 Minamino T, Yujiri T, Papst PJ, Chan ED, Johnson GL, Terada N. MEKK1 suppresses oxidative stress-induced apoptosis of embryonic stem cell-derived cardiac myocytes Proceedings of the National Academy of Sciences of the United States of America. 96: 15127-15132. PMID 10611349 DOI: 10.1073/Pnas.96.26.15127  0.393
1999 Schlesinger TK, Demali KA, Johnson GL, Kazlauskas A. Platelet-derived growth factor-dependent association of the GTPase-activating protein of Ras and Src. The Biochemical Journal. 344: 519-26. PMID 10567236 DOI: 10.1042/Bj3440519  0.508
1999 Schaefer BC, Ware MF, Marrack P, Fanger GR, Kappler JW, Johnson GL, Monks CR. Live cell fluorescence imaging of T cell MEKK2: redistribution and activation in response to antigen stimulation of the T cell receptor. Immunity. 11: 411-21. PMID 10549623 DOI: 10.1016/S1074-7613(00)80116-8  0.395
1999 Sakata N, Kawasome H, Terada N, Gerwins P, Johnson GL, Gelfand EW. Differential activation and regulation of mitogen-activated protein kinases through the antigen receptor and CD40 in human B cells. European Journal of Immunology. 29: 2999-3008. PMID 10508274 DOI: 10.1002/(Sici)1521-4141(199909)29:09<2999::Aid-Immu2999>3.0.Co;2-L  0.484
1999 Nick JA, Avdi NJ, Young SK, McDonald PP, Billstrom MA, Henson PM, Johnson GL, Worthen GS. An intracellular signaling pathway linking lipopolysaccharide stimulation to cellular responses of the human neutrophil: the p38 MAP kinase cascade and its functional significance. Chest. 116: 54S-55S. PMID 10424591 DOI: 10.1378/Chest.116.Suppl_1.54S  0.417
1999 Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL. Epidermal Growth Factor Protects Epithelial Cells against Fas-induced Apoptosis REQUIREMENT FOR Akt ACTIVATION Journal of Biological Chemistry. 274: 17612-17618. PMID 10364198 DOI: 10.1074/Jbc.274.25.17612  0.496
1999 Yujiri T, Fanger GR, Garrington TP, Schlesinger TK, Gibson S, Johnson GL. MEK kinase 1 (MEKK1) transduces c-Jun NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton. Journal of Biological Chemistry. 274: 12605-12610. PMID 10212239 DOI: 10.1074/Jbc.274.18.12605  0.515
1999 Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways Current Opinion in Cell Biology. 11: 211-218. PMID 10209154 DOI: 10.1016/S0955-0674(99)80028-3  0.521
1999 Gibson S, Widmann C, Johnson GL. Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents. Journal of Biological Chemistry. 274: 10916-10922. PMID 10196170 DOI: 10.1074/Jbc.274.16.10916  0.48
1999 Nick JA, Avdi NJ, Young SK, Lehman LA, McDonald PP, Frasch SC, Billstrom MA, Henson PM, Johnson GL, Worthen GS. Selective activation and functional significance of p38alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. The Journal of Clinical Investigation. 103: 851-8. PMID 10079106 DOI: 10.1172/Jci5257  0.457
1999 Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-Activated Protein Kinase: Conservation of a Three-Kinase Module From Yeast to Human Physical Review. 79: 143-180. PMID 9922370 DOI: 10.1152/Physrev.1999.79.1.143  0.481
1998 Knall C, Johnson GL. G-protein regulatory pathways: Rocketing into the twenty-first century. Journal of Cellular Biochemistry. 72: 137-146. PMID 29345839 DOI: 10.1002/(Sici)1097-4644(1998)72:30/31+<137::Aid-Jcb18>3.0.Co;2-L  0.443
1998 Yujiri T, Sather S, Fanger GR, Johnson GL. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption Science. 282: 1911-1914. PMID 9836645 DOI: 10.1126/Science.282.5395.1911  0.554
1998 Jarpe MB, Widmann C, Knall C, Schlesinger TK, Gibson S, Yujiri T, Fanger GR, Gelfand EW, Johnson GL. Anti-apoptotic versus pro-apoptotic signal transduction: Checkpoints and stop signs along the road to death Oncogene. 17: 1475-1482. PMID 9779994 DOI: 10.1038/Sj.Onc.1202183  0.381
1998 McLeish KR, Knall C, Ward RA, Gerwins P, Coxon PY, Klein JB, Johnson GL. Activation of mitogen-activated protein kinase cascades during priming of human neutrophils by TNF-alpha and GM-CSF. Journal of Leukocyte Biology. 64: 537-45. PMID 9766635 DOI: 10.1002/Jlb.64.4.537  0.455
1998 Billstrom MA, Johnson GL, Avdi NJ, Worthen GS. Intracellular Signaling by the Chemokine Receptor US28 during Human Cytomegalovirus Infection Journal of Virology. 72: 5535-5544. PMID 9621010 DOI: 10.1128/Jvi.72.7.5535-5544.1998  0.364
1998 Kawasome H, Papst P, Webb S, Keller GM, Johnson GL, Gelfand EW, Terada N. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity Proceedings of the National Academy of Sciences of the United States of America. 95: 5033-5038. PMID 9560223 DOI: 10.1073/Pnas.95.9.5033  0.423
1998 Widmann C, Gerwins P, Johnson NL, Jarpe MB, Johnson GL. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Molecular and Cellular Biology. 18: 2416-2429. PMID 9528810 DOI: 10.1128/Mcb.18.4.2416  0.519
1998 Widmann C, Gibson S, Johnson GL. Caspase-dependent Cleavage of Signaling Proteins during Apoptosis A TURN-OFF MECHANISM FOR ANTI-APOPTOTIC SIGNALS Journal of Biological Chemistry. 273: 7141-7147. PMID 9507028 DOI: 10.1074/Jbc.273.12.7141  0.532
1998 Fanger GR, Widmann C, Porter AC, Sather S, Johnson GL, Vaillancourt RR. 14-3-3 proteins interact with specific MEK kinases Journal of Biological Chemistry. 273: 3476-3483. PMID 9452471 DOI: 10.1074/Jbc.273.6.3476  0.455
1998 Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL. [d-Arg1,d-Phe5,d-Trp7,9,Leu11]Substance P Acts as a Biased Agonist toward Neuropeptide and Chemokine Receptors Journal of Biological Chemistry. 273: 3097-3104. PMID 9446627 DOI: 10.1074/Jbc.273.5.3097  0.342
1997 Widmann C, Johnson NL, Gardner AM, Smith RJ, Johnson GL. Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1. Oncogene. 15: 2439-47. PMID 9395240 DOI: 10.1038/Sj.Onc.1201421  0.702
1997 Fanger GR, Johnson NL, Johnson GL. MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42 The Embo Journal. 16: 4961-4972. PMID 9305638 DOI: 10.1093/Emboj/16.16.4961  0.549
1997 Cardone MH, Salvesen GS, Widmann C, Johnson G, Frisch SM. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell. 90: 315-23. PMID 9244305 DOI: 10.1016/S0092-8674(00)80339-6  0.465
1997 Ishizuka T, Terada N, Gerwins P, Hamelmann E, Oshiba A, Fanger GR, Johnson GL, Gelfand EW. Mast cell tumor necrosis factor alpha production is regulated by MEK kinases. Proceedings of the National Academy of Sciences of the United States of America. 94: 6358-63. PMID 9177222 DOI: 10.1073/Pnas.94.12.6358  0.52
1997 Knall C, Worthen GS, Johnson GL. Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases Proceedings of the National Academy of Sciences of the United States of America. 94: 3052-3057. PMID 9096344 DOI: 10.1073/Pnas.94.7.3052  0.542
1997 Gerwins P, Blank JL, Johnson GL. Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway. The Journal of Biological Chemistry. 272: 8288-95. PMID 9079650 DOI: 10.1074/Jbc.272.13.8288  0.539
1997 Nick JA, Avdi NJ, Young SK, Knall C, Gerwins P, Johnson GL, Worthen GS. Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP. The Journal of Clinical Investigation. 99: 975-86. PMID 9062356 DOI: 10.1172/Jci119263  0.521
1997 Fanger GR, Gerwins P, Widmann C, Jarpe MB, Johnson GL. MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases? Current Opinion in Genetics & Development. 7: 67-74. PMID 9024636 DOI: 10.1016/S0959-437X(97)80111-6  0.541
1997 Ishizuka T, Sakata N, Johnson GL, Gelfand EW, Terada N. Rapamycin Potentiates Dexamethasone-Induced Apoptosis and Inhibits JNK Activity in Lymphoblastoid Cells Biochemical and Biophysical Research Communications. 230: 386-391. PMID 9016789 DOI: 10.1006/Bbrc.1996.5967  0.456
1997 Bunn P, Chan D, Johnson G, Heasley L, Stewart J, Gera L, Brenner D, Helfrich B. Anti-growth factor therapy for lung cancer Lung Cancer. 18: 10-11. DOI: 10.1016/S0169-5002(97)83860-3  0.531
1996 Avdi NJ, Winston BW, Russel M, Young SK, Johnson GL, Scott Worthent G. Activation of MEKK by formyl-methionyl-leucyl-phenylalanine in human neutrophils: Mapping pathways for mitogen-activated protein kinase activation Journal of Biological Chemistry. 271: 33598-33606. PMID 8969228 DOI: 10.1074/Jbc.271.52.33598  0.532
1996 Wang H, Johnson GL, Liu X, Malbon CC. Repression of Adipogenesis by Adenylyl Cyclase Stimulatory G-protein α Subunit Is Expressed within Region 146-220 Journal of Biological Chemistry. 271: 22022-22029. PMID 8703008 DOI: 10.1074/Jbc.271.36.22022  0.34
1996 Vaillancourt RR, Gardner AM, Kazlauskas A, Johnson GL. The kinase-inactive PDGF beta-receptor mediates activation of the MAP kinase cascade via the endogenous PDGF alpha-receptor in HepG2 cells. Oncogene. 13: 151-9. PMID 8700541  0.617
1996 Gardner AM, Johnson GL. Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. The Journal of Biological Chemistry. 271: 14560-6. PMID 8662985 DOI: 10.1074/Jbc.271.24.14560  0.681
1996 Ishizuka T, Oshiba A, Sakata N, Terada N, Johnson GL, Gelfand EW. Aggregation of the FcϵRI on Mast Cells Stimulates c-Jun Amino-terminal Kinase Activity A RESPONSE INHIBITED BY WORTMANNIN Journal of Biological Chemistry. 271: 12762-12766. PMID 8662803 DOI: 10.1074/Jbc.271.22.12762  0.562
1996 Johnson NL, Gardner AM, Diener KM, Lange-Carter CA, Gleavy J, Jarpe MB, Minden A, Karin M, Zon LI, Johnson GL. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. The Journal of Biological Chemistry. 271: 3229-37. PMID 8621725 DOI: 10.1074/Jbc.271.6.3229  0.718
1996 Blank JL, Gerwins P, Elliott EM, Sather S, Johnson GL. Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3 regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase Journal of Biological Chemistry. 271: 5361-5368. PMID 8621389 DOI: 10.1074/Jbc.271.10.5361  0.536
1996 Heasley LE, Zamarripa J, Storey B, Helfrich B, Mitchell FM, Bunn PA, Johnson GL. Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G alpha 16. The Journal of Biological Chemistry. 271: 349-54. PMID 8550585 DOI: 10.1074/Jbc.271.1.349  0.689
1995 Qian NX, Russell M, Johnson GL. Acetylcholine muscarinic receptor regulation of the Ras/Raf/MAP kinase pathway. Life Sciences. 56: 945-9. PMID 10188797 DOI: 10.1016/0024-3205(95)00032-2  0.491
1995 Sakata N, Patel HR, Terada N, Aruffo A, Johnson GL, Gelfand EW. Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells. Journal of Biological Chemistry. 270: 30823-30828. PMID 8530526 DOI: 10.1074/Jbc.270.51.30823  0.486
1995 Lange-Carter CA, Johnson GL. Assay of MEK kinases. Methods in Enzymology. 255: 290-301. PMID 8524113 DOI: 10.1016/S0076-6879(95)55032-1  0.456
1995 Winston BW, Lange-Carter CA, Gardner AM, Johnson GL, Riches DW. Tumor necrosis factor alpha rapidly activates the mitogen-activated protein kinase (MAPK) cascade in a MAPK kinase kinase-dependent, c-Raf-1-independent fashion in mouse macrophages. Proceedings of the National Academy of Sciences of the United States of America. 92: 1614-8. PMID 7878028 DOI: 10.1073/Pnas.92.5.1614  0.684
1995 Russell M, Lange-Carter CA, Johnson GL. Direct Interaction between Ras and the Kinase Domain of Mitogen-activated Protein Kinase Kinase Kinase (MEKK1) Journal of Biological Chemistry. 270: 11757-11760. PMID 7744823 DOI: 10.1074/Jbc.270.20.11757  0.488
1995 Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M. Identification of a dual specificity kinase that activates the jun kinases and p38-Mpk2 Science. 268: 286-290. PMID 7716521 DOI: 10.1126/Science.7716521  0.549
1995 Dhanasekaran N, Heasley LE, Johnson GL. G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocrine Reviews. 16: 259-70. PMID 7671848 DOI: 10.1210/Edrv-16-3-259  0.613
1995 Buhl AM, Osawa S, Johnson GL. Mitogen-activated Protein Kinase Activation Requires Two Signal Inputs from the Human Anaphylatoxin C5a Receptor Journal of Biological Chemistry. 270: 19828-19832. PMID 7649993 DOI: 10.1074/Jbc.270.34.19828  0.467
1995 Prasad MV, Dermott JM, Heasley LE, Johnson GL, Dhanasekaran N. Activation of Jun kinase/stress-activated protein kinase by GTPase-deficient mutants of G alpha 12 and G alpha 13. The Journal of Biological Chemistry. 270: 18655-9. PMID 7629196 DOI: 10.1074/Jbc.270.31.18655  0.628
1995 Mitchell FM, Russell M, Johnson GL. Differential calcium dependence in the activation of c-Jun kinase and mitogen-activated protein kinase by muscarinic acetylcholine receptors in rat 1a cells. The Biochemical Journal. 381-4. PMID 7625999 DOI: 10.1042/Bj3090381  0.453
1995 Buhl AM, Johnson NL, Dhanasekaran N, Johnson GL. Gα12 and Gα13 Stimulate Rho-dependent Stress Fiber Formation and Focal Adhesion Assembly Journal of Biological Chemistry. 270: 24631-24634. PMID 7559569 DOI: 10.1074/Jbc.270.42.24631  0.326
1995 Vaillancourt RR, Heasley LE, Zamarripa J, Storey B, Valius M, Kazlauskas A, Johnson GL. Mitogen-activated protein kinase activation is insufficient for growth factor receptor-mediated PC12 cell differentiation. Molecular and Cellular Biology. 15: 3644-53. PMID 7540718 DOI: 10.1128/Mcb.15.7.3644  0.689
1995 Mitchell FM, Heasley LE, Qian NX, Zamarripa J, Johnson GL. Differential modulation of bombesin-stimulated phospholipase C beta and mitogen-activated protein kinase activity by [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P. The Journal of Biological Chemistry. 270: 8623-8. PMID 7536738 DOI: 10.1074/Jbc.270.15.8623  0.643
1995 Qian N, Mitchell FM, Johnson GL. Role of ras in muscarinic Ml and M2 acetylcholine receptor regulation of the mitogen-activated protein kinase stimulatory pathway Life Sciences. 56: 1030. DOI: 10.1016/0024-3205(95)93773-8  0.443
1994 Blumer KJ, Johnson GL, Lange-Carter CA. Mammalian mitogen-activated protein kinase kinase kinase (MEKK) can function in a yeast mitogen-activated protein kinase pathway downstream of protein kinase C. Proceedings of the National Academy of Sciences of the United States of America. 91: 4925-9. PMID 8197159 DOI: 10.1073/Pnas.91.11.4925  0.529
1994 Franklin RA, Tordai A, Patel H, Gardner AM, Johnson GL, Gelfand EW. Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. The Journal of Clinical Investigation. 93: 2134-40. PMID 8182145 DOI: 10.1172/Jci117209  0.655
1994 Lange-Carter CA, Pleiman C, Johnson GL. A Novel Upstream Activator in the Mitogen-Activated Protein Kinase Signal Transduction Pathway Recent Progress in Hormone Research. 49: 341-345. PMID 8146429 DOI: 10.1016/B978-0-12-571149-4.50022-2  0.537
1994 Russell M, Winitz S, Johnson GL. Acetylcholine muscarinic m1 receptor regulation of cyclic AMP synthesis controls growth factor stimulation of Raf activity. Molecular and Cellular Biology. 14: 2343-51. PMID 8139539 DOI: 10.1128/Mcb.14.4.2343  0.517
1994 Tordai A, Franklin RA, Patel H, Gardner AM, Johnson GL, Gelfand EW. Cross-linking of surface IgM stimulates the Ras/Raf-1/MEK/MAPK cascade in human B lymphocytes. The Journal of Biological Chemistry. 269: 7538-43. PMID 8125975  0.627
1994 Buhl AM, Avdi N, Worthen GS, Johnson GL. Mapping of the C5a receptor signal transduction network in human neutrophils Proceedings of the National Academy of Sciences of the United States of America. 91: 9190-9194. PMID 8090790 DOI: 10.1073/Pnas.91.19.9190  0.457
1994 Blumer KJ, Johnson GL. Diversity in function and regulation of MAP kinase pathways. Trends in Biochemical Sciences. 19: 236-40. PMID 8073500 DOI: 10.1016/0968-0004(94)90147-3  0.503
1994 Lange-Carter CA, Johnson GL. Ras-Dependent Growth Factor Regulation of MEK Kinase in PC12 Cells Science. 265: 1458-1461. PMID 8073291 DOI: 10.1126/Science.8073291  0.54
1994 Worthen GS, Avdi N, Buhl AM, Suzuki N, Johnson GL. FMLP activates Ras and Raf in human neutrophils. Potential role in activation of MAP kinase. Journal of Clinical Investigation. 94: 815-823. PMID 8040337 DOI: 10.1172/Jci117401  0.506
1994 Johnson GL, Vaillancourt RR. Sequential protein kinase reactions controlling cell growth and differentiation Current Opinion in Cell Biology. 6: 230-238. PMID 8024815 DOI: 10.1016/0955-0674(94)90141-4  0.518
1994 Gardner AM, Vaillancourt RR, Lange-Carter CA, Johnson GL. MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity. Molecular Biology of the Cell. 5: 193-201. PMID 8019005 DOI: 10.1091/Mbc.5.2.193  0.682
1994 Johnson GL, Gardner AM, Lange-Carter C, Qian NX, Russell M, Winitz S. How does the G protein, Gi2, transduce mitogenic signals? Journal of Cellular Biochemistry. 54: 415-22. PMID 8014190 DOI: 10.1002/Jcb.240540408  0.694
1994 Minden A, Lin A, McMahon M, Lange-Carter C, Dérijard B, Davis RJ, Johnson GL, Karin M. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK Science. 266: 1719-1723. PMID 7992057 DOI: 10.1126/Science.7992057  0.521
1994 Vaillancourt RR, Gardner AM, Johnson GL. B-Raf-dependent regulation of the MEK-1/mitogen-activated protein kinase pathway in PC12 cells and regulation by cyclic AMP. Molecular and Cellular Biology. 14: 6522-30. PMID 7935374 DOI: 10.1128/Mcb.14.10.6522  0.686
1994 Winitz S, Russell M, Johnson GL. Construction of mutant and chimeric G-protein alpha subunits. Methods in Enzymology. 237: 321-6. PMID 7935008 DOI: 10.1016/S0076-6879(94)37072-9  0.321
1994 Gardner AM, Lange-Carter CA, Vaillancourt RR, Johnson GL. Measuring activation of kinases in mitogen-activated protein kinase regulatory network. Methods in Enzymology. 238: 258-70. PMID 7799792 DOI: 10.1016/0076-6879(94)38024-4  0.658
1993 Pleiman CM, Clark MR, Gauen LK, Winitz S, Coggeshall KM, Johnson GL, Shaw AS, Cambier JC. Mapping of sites on the Src family protein tyrosine kinases p55blk, p59fyn, and p56lyn which interact with the effector molecules phospholipase C-gamma 2, microtubule-associated protein kinase, GTPase-activating protein, and phosphatidylinositol 3-kinase. Molecular and Cellular Biology. 13: 5877-87. PMID 8395016 DOI: 10.1128/mcb.13.9.5877-5887.1993  0.507
1993 Gardner AM, Vaillancourt RR, Johnson GL. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins. The Journal of Biological Chemistry. 268: 17896-901. PMID 8394352  0.671
1993 Buhl AM, Eisfelder BJ, Worthen GS, Johnson GL, Russell M. Selective coupling of the human anaphylatoxin C5a receptor and α16 in human kidney 293 cells Febs Letters. 323: 132-134. PMID 8388335 DOI: 10.1016/0014-5793(93)81464-B  0.307
1993 Wadzinski BE, Wheat WH, Jaspers S, Peruski LF, Lickteig RL, Johnson GL, Klemm DJ. Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation Molecular and Cellular Biology. 13: 2822-2834. PMID 8386317 DOI: 10.1128/Mcb.13.5.2822  0.461
1993 Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science (New York, N.Y.). 260: 315-9. PMID 8385802 DOI: 10.1126/Science.8385802  0.689
1993 Qian NX, Winitz S, Johnson GL. Epitope-tagged Gq alpha subunits: expression of GTPase-deficient alpha subunits persistently stimulates phosphatidylinositol-specific phospholipase C but not mitogen-activated protein kinase activity regulated by the M1 muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America. 90: 4077-81. PMID 7683419 DOI: 10.1073/Pnas.90.9.4077  0.465
1993 Watkins DC, Johnson GL, Malbon CC. Regulation of the differentiation of teratocarcinoma cells into primitive endoderm by G alpha i2. Science (New York, N.Y.). 258: 1373-5. PMID 1455234 DOI: 10.1126/Science.1455234  0.359
1992 Gupta SK, Gallego C, Lowndes JM, Pleiman CM, Sable C, Eisfelder BJ, Johnson GL. Analysis of the fibroblast transformation potential of GTPase-deficient gip2 oncogenes. Molecular and Cellular Biology. 12: 190-197. PMID 1729598 DOI: 10.1128/Mcb.12.1.190  0.345
1992 Johnson GL, Dhanasekaran N, Gupta SK, Lowndes JM, Vaillancourt RR, Ruoho AE. Genetic and structural analysis of G protein alpha subunit regulatory domains. Journal of Cellular Biochemistry. 47: 136-46. PMID 1661737 DOI: 10.1002/Jcb.240470207  0.358
1992 Gupta SK, Gallego C, Johnson GL. Mitogenic pathways regulated by G protein oncogenes. Molecular Biology of the Cell. 3: 123-128. PMID 1550954 DOI: 10.1091/Mbc.3.1.123  0.38
1992 Gallego C, Gupta SK, Winitz S, Eisfelder BJ, Johnson GL. Myristoylation of the G alpha i2 polypeptide, a G protein alpha subunit, is required for its signaling and transformation functions. Proceedings of the National Academy of Sciences of the United States of America. 89: 9695-9699. PMID 1409685 DOI: 10.1073/Pnas.89.20.9695  0.387
1992 Abdel-Hafiz HA, Heasley LE, Kyriakis JM, Avruch J, Kroll DJ, Johnson GL, Hoeffler JP. Activating transcription factor-2 DNA-binding activity is stimulated by phosphorylation catalyzed by p42 and p54 microtubule-associated protein kinases. Molecular Endocrinology (Baltimore, Md.). 6: 2079-89. PMID 1337144 DOI: 10.1210/Mend.6.12.1337144  0.674
1992 Gallego C, Gupta SK, Heasley LE, Qian NX, Johnson GL. Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat 1a cells. Proceedings of the National Academy of Sciences of the United States of America. 89: 7355-9. PMID 1323832 DOI: 10.1073/Pnas.89.16.7355  0.721
1992 Heasley LE, Johnson GL. The beta-PDGF receptor induces neuronal differentiation of PC12 cells. Molecular Biology of the Cell. 3: 545-53. PMID 1319243 DOI: 10.1091/Mbc.3.5.545  0.665
1991 Heasley LE, Benedict S, Gleavy J, Johnson GL. Requirement of the adenovirus E1A transformation domain 1 for inhibition of PC12 cell neuronal differentiation. Cell Regulation. 2: 479-89. PMID 1832020 DOI: 10.1091/Mbc.2.6.479  0.62
1991 Gupta SK, Dhanasekaran N, Heasley LE, Johnson GL. Activating mutations in the NH2- and COOH-terminal moieties of the Gs alpha subunit have dominant phenotypes and distinguishable kinetics of adenylyl cyclase stimulation. Journal of Cellular Biochemistry. 47: 359-68. PMID 1665495 DOI: 10.1002/Jcb.240470410  0.588
1990 Gupta SK, Diez E, Heasley LE, Osawa S, Johnson GL. A G protein mutant that inhibits thrombin and purinergic receptor activation of phospholipase A2. Science (New York, N.Y.). 249: 662-6. PMID 2166341 DOI: 10.1126/Science.2166341  0.592
1990 Weiss ER, Heller-Harrison RA, Diez E, Crasnier M, Malbon CC, Johnson GL. Rhodopsin expressed in Chinese hamster ovary cells regulates adenylyl cyclase activity. Journal of Molecular Endocrinology. 4: 71-9. PMID 2108693 DOI: 10.1677/Jme.0.0040071  0.424
1990 Osawa S, Heasley LE, Dhanasekaran N, Gupta SK, Woon CW, Berlot C, Johnson GL. Mutation of the Gs protein alpha subunit NH2 terminus relieves an attenuator function, resulting in constitutive adenylyl cyclase stimulation. Molecular and Cellular Biology. 10: 2931-40. PMID 1692962 DOI: 10.1128/Mcb.10.6.2931  0.587
1989 Johnson GL, Dhanasekaran N. The G-protein family and their interaction with receptors. Endocrine Reviews. 10: 317-31. PMID 2550214 DOI: 10.1210/Edrv-10-3-317  0.378
1989 Woon CW, Heasley L, Osawa S, Johnson GL. Mutation of glycine 49 to valine in the alpha subunit of GS results in the constitutive elevation of cyclic AMP synthesis. Biochemistry. 28: 4547-51. PMID 2548581 DOI: 10.1021/Bi00437A006  0.641
1988 Weiss ER, Kelleher DJ, Woon CW, Soparkar S, Osawa S, Heasley LE, Johnson GL. Receptor activation of G proteins. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 2: 2841-8. PMID 3139484 DOI: 10.1096/Fasebj.2.13.3139484  0.6
1987 Wolleben CD, McPherson RK, Rulfs J, Johnson GL, Miller TB. Phosphorylation of rat heart glycogen synthase: studies in cardiomyocytes and in vitro phosphorylations with cAMP-dependent kinase and protein phosphatase-1. Biochimica Et Biophysica Acta. 928: 98-106. PMID 3030451 DOI: 10.1016/0167-4889(87)90090-5  0.312
1980 Kaslow HR, Johnson GL, Brothers VM, Bourne HR. A regulatory component of adenylate cyclase from human erythrocyte membranes. The Journal of Biological Chemistry. 255: 3736-41. PMID 7364766  0.422
1980 Johnson GL, Kaslow HR, Farfel Z, Bourne HR. Genetic analysis of hormone-sensitive adenylate cyclase. Advances in Cyclic Nucleotide Research. 13: 1-37. PMID 6251703  0.409
1979 Kaslow HR, Farfel Z, Johnson GL, Bourne HR. Adenylate cyclase assembled in vitro: cholera toxin substrates determine different patterns of regulation by isoproterenol and guanosine 5'-triphosphate. Molecular Pharmacology. 15: 472-83. PMID 226858  0.47
1979 Johnson GL, Bourne HR, Gleason MK, Coffino P, Insel PA, Melmon KL. Isolation and characterization of S49 lymphoma cells deficient in beta-adrenergic receptors: relation of receptor number to activation of adenylate cyclase. Molecular Pharmacology. 15: 16-27. PMID 34089  0.476
1978 Johnson GL, Kaslow HR, Bourne HR. Reconstitution of cholera toxin-activated adenylate cyclase. Proceedings of the National Academy of Sciences of the United States of America. 75: 3113-7. PMID 277913 DOI: 10.1073/Pnas.75.7.3113  0.472
1978 Johnson GL, Kaslow HR, Bourne HR. Genetic evidence that cholera toxin substrates are regulatory components of adenylate cyclase. The Journal of Biological Chemistry. 253: 7120-3. PMID 212417  0.512
1978 Naya-Vigne J, Johnson GL, Bourne HR, Coffino P. Complementation analysis of hormone-sensitive adenylate cyclase. Nature. 272: 720-2. PMID 205796 DOI: 10.1038/272720A0  0.489
1977 Johnson GL, Bourne HR. Influence of cholera toxin on the regulation of adenylate cyclase by GTP. Biochemical and Biophysical Research Communications. 78: 792-8. PMID 199187 DOI: 10.1016/0006-291X(77)90249-2  0.511
1975 Clark RB, Su YF, Ortmann R, Cubeddu L, Johnson GL, Perkins JP. Factors influencing the effect of hormones on the accumulation of cyclic AMP in cultured human astrocytoma cells. Metabolism: Clinical and Experimental. 24: 343-58. PMID 165356 DOI: 10.1016/0026-0495(75)90115-8  0.648
Low-probability matches (unlikely to be authored by this person)
2004 Lieber JG, Webb S, Suratt BT, Young SK, Johnson GL, Keller GM, Worthen GS. The in vitro production and characterization of neutrophils from embryonic stem cells. Blood. 103: 852-9. PMID 14525782 DOI: 10.1182/Blood-2003-04-1030  0.299
1990 Johnson GL. G Proteins. ADP-ribosylating toxins and G proteins: Insights into signal transduction Cell. 62: 627-628. DOI: 10.1016/0092-8674(90)90107-P  0.298
2017 Zawistowski JS, Goulet DR, Johnson GL. Landscaping a chromatin response to MEK inhibition. Cell Cycle (Georgetown, Tex.). 0. PMID 28287892 DOI: 10.1080/15384101.2017.1302232  0.297
2019 Shih C, Blakeley J, Clapp DW, Armstrong AE, Wolters P, Dombi E, Cutter G, Ullrich NJ, Allen J, Packer R, Goldman S, Gutmann DH, Plotkin S, Rosser T, Robertson K, ... ... Johnson G, et al. Abstract CT233: Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct233  0.297
1990 Osawa S, Dhanasekaran N, Woon CW, Johnson GL. G alpha i-G alpha s chimeras define the function of alpha chain domains in control of G protein activation and beta gamma subunit complex interactions. Cell. 63: 697-706. PMID 2121366 DOI: 10.1016/0092-8674(90)90136-3  0.297
2001 Schaefer BC, Ware MF, Marrack P, Fanger GR, Kappler JW, Johnson GL, Monks CRF. Erratum: Live cell fluorescence imaging of T cell MEKK2: Redistribution and activation in response to antigen stimulation of the T cell receptor (Immunity (October 1999)) Immunity. 14: 655-656. DOI: 10.1016/S1074-7613(01)00138-8  0.297
1992 Dhanasekaran N, Osawa S, Johnson GL. The NH2-terminal alpha subunit attenuator domain confers regulation of G protein activation by beta gamma complexes. Journal of Cellular Biochemistry. 47: 352-8. PMID 1795017 DOI: 10.1002/Jcb.240470409  0.296
1987 Wessling-Resnick M, Johnson GL. Kinetic and hydrodynamic properties of transducin: comparison of physical and structural parameters for GTP-binding regulatory proteins. Biochemistry. 26: 4316-23. PMID 3117101 DOI: 10.1021/Bi00388A020  0.295
2013 Samykutty A, Shetty AV, Dakshinamoorthy G, Bartik MM, Johnson GL, Webb B, Zheng G, Chen A, Kalyanasundaram R, Munirathinam G. Piperine, a Bioactive Component of Pepper Spice Exerts Therapeutic Effects on Androgen Dependent and Androgen Independent Prostate Cancer Cells. Plos One. 8: e65889. PMID 23824300 DOI: 10.1371/Journal.Pone.0065889  0.294
2002 Grabarek J, Dragan M, Lee BW, Johnson GL, Darzynkiewicz Z. Activation of chymotrypsin-like serine protease(s) during apoptosis detected by affinity-labeling of the enzymatic center with fluoresceinated inhibitor. International Journal of Oncology. 20: 225-33. PMID 11788882  0.293
2018 Oprea TI, Bologa CG, Brunak S, Campbell A, Gan GN, Gaulton A, Gomez SM, Guha R, Hersey A, Holmes J, Jadhav A, Jensen LJ, Johnson GL, Karlson A, Leach AR, et al. Unexplored therapeutic opportunities in the human genome. Nature Reviews. Drug Discovery. PMID 29472638 DOI: 10.1038/Nrd.2018.14  0.293
2023 Asquith CRM, East MP, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells CI, Axtman AD, Drewry DH, Tizzard GJ, Poso A, Willson TM, Johnson GL. Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships. Biorxiv : the Preprint Server For Biology. PMID 38234837 DOI: 10.1101/2023.12.28.573261  0.293
2007 Griffin RJ, Williams BW, Bischof JC, Olin M, Johnson GL, Lee BW. Use of a fluorescently labeled poly-caspase inhibitor for in vivo detection of apoptosis related to vascular-targeting agent arsenic trioxide for cancer therapy. Technology in Cancer Research & Treatment. 6: 651-4. PMID 17994796 DOI: 10.1177/153303460700600609  0.291
2008 Lee BW, Olin MR, Johnson GL, Griffin RJ. In vitro and in vivo apoptosis detection using membrane permeant fluorescent-labeled inhibitors of caspases. Methods in Molecular Biology (Clifton, N.J.). 414: 109-35. PMID 18175816 DOI: 10.1007/978-1-59745-339-4_10  0.29
2018 Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, ... ... Johnson GL, et al. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. Plos One. 13: e0197350. PMID 29897904 DOI: 10.1371/Journal.Pone.0197350  0.289
2005 Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. The American Journal of Pathology. 167: 1763-75. PMID 16314486 DOI: 10.1016/S0002-9440(10)61257-6  0.288
2014 Abell AN, Johnson GL. Implications of Mesenchymal Cells in Cancer Stem Cell Populations: Relevance to EMT. Current Pathobiology Reports. 2: 21-26. PMID 25530923 DOI: 10.1007/S40139-013-0034-7  0.288
2016 Brighton HE, Angus S, Bo T, Darr D, Sharpless NE, Johnson GL, Bear JE. Abstract 4382: Intravital imaging of endogenous BRAFV600E melanoma reveals plasticity of tumor response and resistance to trametinib over time Cancer Research. 76: 4382-4382. DOI: 10.1158/1538-7445.Am2016-4382  0.288
1993 Senkfor SI, Johnson GL, Berl T. A molecular map of G protein alpha chains in microdissected rat nephron segments. Journal of Clinical Investigation. 92: 786-790. PMID 8349818 DOI: 10.1172/Jci116651  0.288
2024 Joisa CU, Chen KA, Beville S, Stuhlmiller T, Berginski ME, Okumu D, Golitz BT, East MP, Johnson GL, Gomez SM. Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 29: 276-290. PMID 38160286  0.286
2021 Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, ... ... Johnson GL, et al. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. Plos One. 16: e0252048. PMID 34264955 DOI: 10.1371/journal.pone.0252048  0.283
1989 Wessling-Resnick M, Johnson GL. Evidence for oligomeric forms of transducins alpha subunit: formation of intermolecular alpha-alpha disulfide linkages. Biochemical and Biophysical Research Communications. 159: 651-7. PMID 2494995 DOI: 10.1016/0006-291X(89)90044-2  0.281
2011 Jordan NV, Johnson GL, Abell AN. Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle (Georgetown, Tex.). 10: 2865-73. PMID 21862874 DOI: 10.4161/Cc.10.17.17188  0.279
2003 Lee BW, Johnson GL, Hed SA, Darzynkiewicz Z, Talhouk JW, Mehrotra S. DEVDase detection in intact apoptotic cells using the cell permeant fluorogenic substrate, (z-DEVD)2-cresyl violet. Biotechniques. 35: 1080-5. PMID 14628683 DOI: 10.2144/03355Pf01  0.279
2022 Murray NH, Asquith CRM, Fang Z, East MP, Ptak N, Smith RW, Vasta JD, Zimprich CA, Corona CR, Robers MB, Johnson GL, Bingman CA, Pagliarini DJ. Small-molecule inhibition of the archetypal UbiB protein COQ8. Nature Chemical Biology. PMID 36302899 DOI: 10.1038/s41589-022-01168-3  0.274
1995 Knall C, Worthen GS, Buhl AM, Johnson GL. IL‐8 Signal Transduction in Human Neutrophils Annals of the New York Academy of Sciences. 766: 288-291. PMID 7486674 DOI: 10.1111/J.1749-6632.1995.Tb26679.X  0.27
2021 Mehta GA, Angus SP, Khella CA, Tong K, Khanna P, Dixon SAH, Verzi MP, Johnson GL, Gatza ML. SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2. Npj Breast Cancer. 7: 40. PMID 33837205 DOI: 10.1038/s41523-021-00248-2  0.268
2014 Stuhlmiller TJ, Earp HS, Johnson GL. Adaptive reprogramming of the breast cancer kinome. Clinical Pharmacology and Therapeutics. 95: 413-5. PMID 24413269 DOI: 10.1038/clpt.2014.8  0.266
2018 Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, et al. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro-Oncology. PMID 29982664 DOI: 10.1093/Neuonc/Noy046  0.266
2021 Yesilkanal AE, Yang D, Valdespino A, Tiwari P, Sabino AU, Nguyen LC, Lee J, Xie XH, Sun S, Dann C, Robinson-Mailman L, Steinberg E, Stuhlmiller T, Frankenberger C, Goldsmith E, ... Johnson GL, et al. Limited inhibition of multiple nodes in a driver network blocks metastasis. Elife. 10. PMID 33973518 DOI: 10.7554/eLife.59696  0.264
1990 Vaillancourt RR, Dhanasekaran N, Johnson GL, Ruoho AE. 2-Azido-[32P]NAD+, a photoactivatable probe for G-protein structure: evidence for holotransducin oligomers in which the ADP-ribosylated carboxyl terminus of alpha interacts with both alpha and gamma subunits. Proceedings of the National Academy of Sciences of the United States of America. 87: 3645-9. PMID 2111013 DOI: 10.1073/Pnas.87.10.3645  0.255
1998 Johnson GL. Sex, size and sight... Trends in Biochemical Sciences. 23: 406. DOI: 10.1016/S0968-0004(98)01269-9  0.249
2021 Cheng C, Reis SA, Adams ET, Fass DM, Angus SP, Stuhlmiller TJ, Richardson J, Olafson H, Wang ET, Patnaik D, Beauchamp RL, Feldman DA, Silva MC, Sur M, Johnson GL, et al. High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy. Scientific Reports. 11: 17029. PMID 34426604 DOI: 10.1038/s41598-021-96227-5  0.241
2012 Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, MacHius M, Johnson GL, et al. Discovery of small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia Acs Medicinal Chemistry Letters. 3: 129-134. DOI: 10.1021/ml200239k  0.241
1975 Johnson GL, Brown JL. Partial purification and characterization of two peptidases from Neurospora crassa. Biochimica Et Biophysica Acta. 370: 530-40. PMID 4280316 DOI: 10.1016/0005-2744(74)90114-4  0.236
2016 Qin Y, Sundaram S, Essaid L, Chen X, Miller SM, Yan F, Darr DB, Galanko JA, Montgomery SA, Major MB, Johnson GL, Troester MA, Makowski L. Weight loss reduces basal-like breast cancer through kinome reprogramming. Cancer Cell International. 16: 26. PMID 27042159 DOI: 10.1186/S12935-016-0300-Y  0.232
2011 Huang W, Umbach DM, Vincent Jordan N, Abell AN, Johnson GL, Li L. Efficiently identifying genome-wide changes with next-generation sequencing data. Nucleic Acids Research. 39: e130. PMID 21803788 DOI: 10.1093/Nar/Gkr592  0.228
2002 Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZDI839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer Seminars in Oncology. 29: 37-46. PMID 11894012  0.226
2022 Karim M, Saul S, Ghita L, Sahoo MK, Ye C, Bhalla N, Lo CW, Jin J, Park JG, Martinez-Gualda B, East MP, Johnson GL, Pinsky BA, Martinez-Sobrido L, Asquith CRM, et al. Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies. Antiviral Research. 105367. PMID 35738348 DOI: 10.1016/j.antiviral.2022.105367  0.215
2017 Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr D, Karagoz K, Sciaky N, Gatza M, Sharpless NE, Johnson GL, Bear JE. New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging. Cancer Research. PMID 29180473 DOI: 10.1158/0008-5472.CAN-17-1653  0.213
2018 Yesilkanal AE, Rabe DC, Tiwari P, Frankenberger C, Johnson GL, Rosner M. Abstract 4179: A novel approach for antimetastatic therapies against TNBC utilizing a physiologic suppressor Tumor Biology. DOI: 10.1158/1538-7445.Am2018-4179  0.213
2007 Malone MH, Sciaky N, Stalheim L, Hahn KM, Linney E, Johnson GL. Laser-scanning velocimetry: a confocal microscopy method for quantitative measurement of cardiovascular performance in zebrafish embryos and larvae. Bmc Biotechnology. 7: 40. PMID 17623073 DOI: 10.1186/1472-6750-7-40  0.212
2016 McNeill R, Stuhlmiller T, Bash R, Khagi S, Johnson G, Miller CR. Tmod-01. Functional Kinome Characterization Of A Diverse Panel Of Glioblastoma Models Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.871  0.211
2021 Kalogirou AS, East MP, Laitinen T, Torrice CD, Maffuid KA, Drewry DH, Koutentis PA, Johnson GL, Crona DJ, Asquith CRM. Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors. Molecules (Basel, Switzerland). 26. PMID 34641454 DOI: 10.3390/molecules26195911  0.205
2013 Biela E, Galas J, Lee B, Johnson GL, Darzynkiewicz Z, Dobrucki JW. Col-F, a fluorescent probe for ex vivo confocal imaging of collagen and elastin in animal tissues. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 83: 533-9. PMID 23404939 DOI: 10.1002/Cyto.A.22264  0.203
2021 Zhu H, Ficarro SB, Alexander WM, Fleming LE, Adelmant G, Zhang T, Willetts M, Decker J, Brehmer S, Krause M, East MP, Gray NS, Johnson GL, Kruppa G, Marto JA. PRM-LIVE with Trapped Ion Mobility Spectrometry and Its Application in Selectivity Profiling of Kinase Inhibitors. Analytical Chemistry. PMID 34606255 DOI: 10.1021/acs.analchem.1c02349  0.198
1979 Germaine GR, Tellefson LM, Johnson GL. Whole saliva proteases: development of methods for determination of origins. Advances in Experimental Medicine and Biology. 107: 849-58. PMID 742517 DOI: 10.1007/978-1-4684-3369-2_95  0.194
2021 Angus SP, Stuhlmiller TJ, Mehta G, Bevill SM, Goulet DR, Olivares-Quintero JF, East MP, Tanioka M, Zawistowski JS, Singh D, Sciaky N, Chen X, He X, Rashid NU, Chollet-Hinton L, ... ... Johnson GL, et al. FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. Npj Breast Cancer. 7: 51. PMID 33980863 DOI: 10.1038/s41523-021-00258-0  0.191
2018 Oprea TI, Bologa CG, Brunak S, Campbell A, Gan GN, Gaulton A, Gomez SM, Guha R, Hersey A, Holmes J, Jadhav A, Jensen LJ, Johnson GL, Karlson A, Leach AR, et al. Unexplored therapeutic opportunities in the human genome. Nature Reviews. Drug Discovery. PMID 29567993 DOI: 10.1038/Nrd.2018.52  0.191
2018 Oprea TI, Jan L, Johnson GL, Roth BL, Ma'ayan A, Schürer S, Shoichet BK, Sklar LA, McManus MT. Far away from the lamppost. Plos Biology. 16: e3000067. PMID 30532236 DOI: 10.1371/Journal.Pbio.3000067  0.185
2014 Tarpley M, Abdissa TT, Johnson GL, Scott JE. Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines. Anticancer Research. 34: 1629-35. PMID 24692691  0.177
2021 Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, Zhang C, Angus SP, Johnson GL, Packer RJ, Allen JC, Ullrich NJ, Goldman S, Gutmann DH, Plotkin SR, et al. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nature Medicine. 27: 165-173. PMID 33442015 DOI: 10.1038/s41591-020-01193-6  0.154
2023 Flint AC, Mitchell DK, Angus SP, Smith AE, Bessler W, Jiang L, Mang H, Li X, Lu Q, Rodriguez B, Sandusky GE, Masters AR, Zhang C, Dang P, Koenig J, ... Johnson GL, et al. Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37406085 DOI: 10.1158/1078-0432.CCR-22-2854  0.153
2021 Yesilkanal AE, Johnson GL, Ramos AF, Rosner MR. New strategies for targeting kinase networks in cancer. The Journal of Biological Chemistry. 101128. PMID 34461089 DOI: 10.1016/j.jbc.2021.101128  0.149
2002 Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma Cancer Research. 62: 3971-3979. PMID 12124329  0.148
1984 Buxser SE, Watson L, Johnson GL. A comparison of binding properties and structure of NGF receptor on PC12 pheochromocytoma and A875 melanoma cells. Journal of Cellular Biochemistry. 22: 219-33. PMID 6323498 DOI: 10.1002/jcb.240220404  0.146
1992 Gioannini TL, Weiss ER, Johnson GL, Hiller JM, Simon EJ. Immunoblots with rhodopsin antisera suggest that a purified mu opioid binding protein has structural characteristics of a G-protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America. 89: 52-5. PMID 1309617 DOI: 10.1073/Pnas.89.1.52  0.143
1989 Jaspers SR, Rulfs J, Johnson GL, Mole JE, Miller TB. Amino-terminal sequence analysis of rat heart and muscle glycogen synthase: homology to the rabbit enzyme and the implications for hormonal control. Archives of Biochemistry and Biophysics. 268: 630-6. PMID 2492421 DOI: 10.1016/0003-9861(89)90330-5  0.136
1988 Arino J, Woon CW, Brautigan DL, Miller TB, Johnson GL. Human liver phosphatase 2A: cDNA and amino acid sequence of two catalytic subunit isotypes Proceedings of the National Academy of Sciences of the United States of America. 85: 4252-4256. PMID 2837763 DOI: 10.1073/Pnas.85.12.4252  0.111
1983 Massague J, Buxser S, Johnson GL, Czech MP. Affinity labeling of a nerve growth factor receptor component on rat pheochromocytoma (PC12) cells. Biochimica Et Biophysica Acta. 693: 205-12. PMID 6295482 DOI: 10.1016/0005-2736(82)90488-6  0.107
1981 Johnson GL, MacAndrew VI, Pilch PF. Identification of the glucagon receptor in rat liver membranes by photoaffinity crosslinking Proceedings of the National Academy of Sciences of the United States of America. 78: 875-878. PMID 6262779 DOI: 10.1073/Pnas.78.2.875  0.093
2006 Doyle JW, Johnson GL, Eshhar N, Hammond D. The use of rabbit polyclonal antibodies to assess neoantigenicity following viral reduction of an alpha-1-proteinase inhibitor preparation. Biologicals : Journal of the International Association of Biological Standardization. 34: 199-207. PMID 16459099 DOI: 10.1016/j.biologicals.2005.09.006  0.085
2017 Zawistowski JS, Bevill SM, Johnson GL. Pharmacologic targeting of drug-induced enhancers. Oncoscience. 4: 43-44. PMID 28781985 DOI: 10.18632/oncoscience.354  0.085
2005 Andrews EW, Taylor MP, Johnson GL, Coad I. The impact of anode cover control and anode assembly design on reduction cell performance - Part 2 Tms Light Metals. 357-362.  0.07
2008 Johnson GL. Preparing for greenhouse gas regulations Sustainable Engineering Forum Conference, Topical Conference At the 2008 Aiche Spring National Meeting. 248-309.  0.067
2004 McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J, Mannel R. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecologic Oncology. 95: 157-64. PMID 15385126 DOI: 10.1016/J.YGYNO.2004.07.008  0.064
2008 Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecologic Oncology. 109: 174-81. PMID 18314182 DOI: 10.1016/J.Ygyno.2008.01.005  0.062
2007 Enriquez LS, Mohammed TL, Johnson GL, Lefor MJ, Beasley MB. Hard metal pneumoconiosis: a case of giant-cell interstitial pneumonitis in a machinist. Respiratory Care. 52: 196-9. PMID 17261209  0.061
2015 Johnson GL, Sarker SJ, Nannini F, Ferrini A, Taylor E, Lass-Flörl C, Mutschlechner W, Bustin SA, Agrawal SG. Aspergillus-Specific Lateral-Flow Device and Real-Time PCR Testing of Bronchoalveolar Lavage Fluid: a Combination Biomarker Approach for Clinical Diagnosis of Invasive Pulmonary Aspergillosis. Journal of Clinical Microbiology. 53: 2103-8. PMID 25903568 DOI: 10.1128/JCM.00110-15  0.06
2011 Irwin MR, Levin MJ, Carrillo C, Olmstead R, Lucko A, Lang N, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, ... Johnson G, et al. Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain, Behavior, and Immunity. 25: 759-66. PMID 21329753 DOI: 10.1016/J.Bbi.2011.02.001  0.059
1993 Magnus P, Giles M, Bonnert R, Johnson G, McQuire L, Deluca M, Merritt A, Kim CS, Vicker N. Synthesis of strychnine and the Wieland-Gumlich aldehyde Journal of the American Chemical Society. 115: 8116-8129. DOI: 10.1021/Ja00071A025  0.057
2013 Johnson GL, Sarker SJ, Hill K, Tsitsikas DA, Morin A, Bustin SA, Agrawal SG. Significant Decline in Galactomannan Signal during Storage of Clinical Serum Samples. International Journal of Molecular Sciences. 14: 12970-7. PMID 23797658 DOI: 10.3390/ijms140712970  0.057
2009 Hayden R, Clair AA, Johnson G, Otto D. The effect of rhythmic auditory stimulation (ras) on physical therapy outcomes for patients in gait training following stroke: A feasibility study International Journal of Neuroscience. 119: 2183-2195. PMID 19916847 DOI: 10.3109/00207450903152609  0.055
1986 Osawa S, Chiu RH, McDonough A, Miller TB, Johnson GL. Isolation of partial cDNAs for rat liver and muscle glycogen phosphorylase isozymes. Febs Letters. 202: 282-8. PMID 2424788 DOI: 10.1016/0014-5793(86)80702-5  0.052
1975 Selman BR, Johnson GL, Giaquinta RT, Dilley RA. Evidence for cyanide and mercury inactivation of endogenous plastocyanin Journal of Bioenergetics. 6: 221-231. DOI: 10.1007/Bf01648964  0.049
2012 Johnson GL, Bibby DF, Wong S, Agrawal SG, Bustin SA. A MIQE-compliant real-time PCR assay for Aspergillus detection. Plos One. 7: e40022. PMID 22808087 DOI: 10.1371/journal.pone.0040022  0.048
2016 Melancon T, Bivona C, Klenke S, Rockey M, Huh J, Henry D, Grauer D, Al-Kasspooles M, Johnson G, Reynolds E, Chapman J. Comparison of postoperative venous thromboembolism incidence in gastrointestinal and gynecologic solid tumors. Thrombosis Research. 147: 104-107. PMID 27728891 DOI: 10.1016/J.Thromres.2016.10.007  0.048
1994 Johnson GL. What Has Archaeology to Do with Faith?. James H. Charlesworth and Walter P. Weaver. The Biblical Archaeologist. 57: 181-182. DOI: 10.2307/3210423  0.043
2009 Utt MD, Johnson GL, Beal WE. The evaluation of corpus luteum blood flow using color-flow Doppler ultrasound for early pregnancy diagnosis in bovine embryo recipients. Theriogenology. 71: 707-15. PMID 18995894 DOI: 10.1016/j.theriogenology.2008.09.032  0.04
2013 Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, Carrillo C, Stanley HA, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, ... ... Johnson G, et al. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 56: 1085-93. PMID 23413415 DOI: 10.1093/Cid/Cis1208  0.039
2009 Johnson GL, Prodgers RA. Conserving an S1/G5/T2 mustard at a Southeast Montana coal mine through nursery propagation and transplanting 26th Annual Meetings of the American Society of Mining and Reclamation and 11th Billings Land Reclamation Symposium 2009. 2: 639-648.  0.037
2022 Almeter PJ, Isaacs JT, Hunter AN, Henderson BS, Platt T, Mitchell BJ, Do D, Brainard AB, Brown JE, Stone RM, Nguyen BH, Warren MF, Bhaktawara SA, Bossle MN, Long LM, ... ... Johnson GL, et al. FDA Approaches in Monitoring Drug Quality, Forces Impacting the Drug Quality, and Recent Alternative Strategies to Assess Quality in the US Drug Supply. Journal of Pharmaceutical Innovation. 1-14. PMID 35677914 DOI: 10.1007/s12247-022-09659-5  0.037
2009 Johnson GL, Sinclair TR, Kenworthy K. Transpiration and normalized difference vegetation index response of seashore paspalum to soil drying Hortscience. 44: 2046-2048.  0.036
2014 Johnson G. Business associates: understanding the true risks. How to keep on top of HIPAA's latest requirements. Health Management Technology. 35: 24-5. PMID 25265674  0.03
2018 Johnson G, Smith J, Peddie J, Peddie L, DeMarco J, Wiedner E. USE OF GLUE-ON SHOES TO IMPROVE CONFORMATIONAL ABNORMALITIES IN TWO ASIAN ELEPHANTS ( ELEPHAS MAXIMUS). Journal of Zoo and Wildlife Medicine : Official Publication of the American Association of Zoo Veterinarians. 49: 183-188. PMID 29517450 DOI: 10.1638/2017-0065R.1  0.029
2003 Frazier M, Thomassen D, Patrinos A, Johnson G, Oliver CE, Uberbacher E. Stepping up the pace of discovery: the genomes to life program. Proceedings / Ieee Computer Society Bioinformatics Conference. Ieee Computer Society Bioinformatics Conference. 2: 2-9. PMID 16826641 DOI: 10.1109/CSB.2003.1227287  0.028
2010 MAGNUS P, GILES M, BONNERT R, JOHNSON G, MCQUIRE L, DELUCA M, MERRITT A, KIM CS, VICKER N. ChemInform Abstract: Synthesis of Strychnine and the Wieland-Gumlich Aldehyde. Cheminform. 25: no-no. DOI: 10.1002/chin.199403219  0.028
2007 Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. The Clinical Journal of Pain. 23: 490-6. PMID 17575488 DOI: 10.1097/AJP.0b013e318065b6c9  0.024
2012 Johnson GL. Denosumab (prolia) for treatment of postmenopausal osteoporosis. American Family Physician. 85: 334-6. PMID 22335312  0.022
2005 Hobeika CM, Mohammed TL, Johnson GL, Hansen K. Kimura's disease: case report and review of the literature. Journal of Thoracic Imaging. 20: 298-300. PMID 16282910 DOI: 10.1097/01.rti.0000181522.10263.c5  0.022
1980 McDonald SA, Johnson GL, Keelan BW, Andrews L. Infrared spectra of hydrogen-bonded .pi. complexes between hydrogen halides and acetylene Journal of the American Chemical Society. 102: 2892-2896. DOI: 10.1021/Ja00529A004  0.021
2002 Johnson GL, Machado RM, Freidl KG, Achenbach ML, Clark PJ, Reidy SK. Evaluation of Raman spectroscopy for determining cis and trans isomers in partially hydrogenated soybean oil Organic Process Research and Development. 6: 637-644. DOI: 10.1021/op0202080  0.021
2021 Zisook S, Mohamad S, Johnson G, Tal I, Villarreal G, Wilcox JA, Shear KM. Clinical implications of co-occurring prolonged grief disorder in patients with treatment-resistant major depressive disorder. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 20: 303-304. PMID 34002524 DOI: 10.1002/wps.20877  0.021
2006 Johnson GL. New standard guides internal and supplier audits Quality Progress. 39: 25-30.  0.02
2014 Johnson GL, Sarker SJ, Bustin SA, Agrawal SG. Insufficient demonstration of long-term stability of Aspergillus galactomannan. Journal of Clinical Microbiology. 52: 4118. PMID 25324240 DOI: 10.1128/JCM.02342-14  0.02
1993 Listemann M, Wressell A, Lassila K, Klotz H, Johnson G, Savoca A. The Influence of Tertiary Amine Structure On Blow-To-Gel Selectivity Journal of Cellular Plastics. 29: 473-474. DOI: 10.1177/0021955X9302900588  0.019
2010 Boutte G, Kelly-Jackson C, Johnson GL. Culturally relevant teaching in science classrooms: Addressing academic achievement, cultural competence, and critical consciousness International Journal of Multicultural Education. 12.  0.019
2012 Wiedner EB, Peddie J, Peddie LR, Abou-Madi N, Kollias GV, Doyle C, Lindsay WA, Isaza R, Terrell S, Lynch TM, Johnson K, Johnson G, Sammut C, Daft B, Uzal F. Strangulating intestinal obstructions in four captive elephants (Elephas maximus and Loxodonta africana). Journal of Zoo and Wildlife Medicine : Official Publication of the American Association of Zoo Veterinarians. 43: 125-30. PMID 22448519 DOI: 10.1638/2011-0088.1  0.018
2004 Hanson CL, Pierson FB, Johnson GL. Dual-gauge system for measuring precipitation: Historical development and use Journal of Hydrologic Engineering. 9: 350-359. DOI: 10.1061/(ASCE)1084-0699(2004)  0.016
2004 Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. The Journal of Pain : Official Journal of the American Pain Society. 5: 344-56. PMID 15336639 DOI: 10.1016/j.jpain.2004.06.001  0.016
2019 Asbell P, Messmer E, Chan C, Johnson G, Sloesen B, Cook N. Defining the needs and preferences of patients with dry eye disease. Bmj Open Ophthalmology. 4: e000315. PMID 31909189 DOI: 10.1136/bmjophth-2019-000315  0.015
2013 Lee JL, Gilleland J, Campbell RM, Simpson P, Johnson GL, Dooley KJ, Blount RL. Health care utilization and psychosocial factors in pediatric noncardiac chest pain. Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association. 32: 320-7. PMID 22486549 DOI: 10.1037/a0027806  0.015
2000 Johnson GL, Nelson RM. Informed consent and assent in human subject research. Journal of Public Health Management and Practice : Jphmp. 6: 9-18. PMID 18019956  0.015
2018 Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ. The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients. The American Journal of Managed Care. 24: S475-S482. PMID 30452199  0.015
2009 Gilleland J, Blount RL, Campbell RM, Johnson GL, Dooley KJ, Simpson P. Brief report: Psychosocial factors and pediatric noncardiac chest pain. Journal of Pediatric Psychology. 34: 1170-4. PMID 19321718 DOI: 10.1093/jpepsy/jsp020  0.014
2018 Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ. Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis. The American Journal of Managed Care. 24: S468-S474. PMID 30452198  0.014
2002 Keese JM, Johnson G. Web distribution of diagnostic images requires new security efforts. Radiology Management. 24: 40-1. PMID 11857995  0.013
2022 Hammer E, Sanfilippo JL, Johnson G, Hetzel S. Association of in-competition injury risk and the degree of rapid weight cutting prior to competition in division I collegiate wrestlers. British Journal of Sports Medicine. PMID 36261252 DOI: 10.1136/bjsports-2022-105760  0.013
1974 Thompson RD, Johnson GL. Thin-layer chromatography of various analgesics, antipyretics and anti-inflammatory agents. Journal of Chromatography. 88: 361-3. PMID 4360690 DOI: 10.1016/S0021-9673(00)83162-3  0.013
2019 Messmer E, Chan C, Asbell P, Johnson G, Sloesen B, Cook N. Comparing the needs and preferences of patients with moderate and severe dry eye symptoms across four countries. Bmj Open Ophthalmology. 4: e000360. PMID 31909193 DOI: 10.1136/bmjophth-2019-000360  0.012
2008 Taylor PT, Kim HR, Kutina J, Johnson GL. Geohazard assessment from satellite magnetic data modeling - With examples from the Arctic Margin along the Canada Basin and the Korean Peninsula along 40°N (latitude) parallel Earth, Planets and Space. 60: 497-503.  0.012
2007 Ferozali F, Johnson G, Cavagnaro A. Health benefits and reductions in bacteria from enhanced oral care. Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry For the Handicapped, and the American Society For Geriatric Dentistry. 27: 168-76. PMID 17990475 DOI: 10.1111/j.1754-4505.2007.tb00342.x  0.011
2012 Baumhardt RL, Johnson GL, Schwartz RC. Residue and long-term tillage and crop rotation effects on simulated rain infiltration and sediment transport Soil Science Society of America Journal. 76: 1370-1378. DOI: 10.2136/sssaj2011.0331  0.011
2004 Oddone EZ, Olsen MK, Lindquist JH, Orr M, Horner R, Reda D, Lavori P, Johnson G, Collins J, Feussner JR. Enrollment in clinical trials according to patients race: experience from the VA Cooperative Studies Program (1975-2000). Controlled Clinical Trials. 25: 378-87. PMID 15296812 DOI: 10.1016/j.cct.2004.05.001  0.011
2012 Almeter PJ, Johnson GL, Saenz R. Optimizing 340B purchasing practices. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 69: 1366-8, 1370-1. PMID 22855101 DOI: 10.2146/ajhp110626  0.011
2012 Jakobsson SP, Johnson GL. Intraglacial volcanism in the Western Volcanic Zone, Iceland Bulletin of Volcanology. 74: 1141-1160. DOI: 10.1007/s00445-012-0589-x  0.011
2013 Lee JL, Gilleland J, Campbell RM, Johnson GL, Simpson P, Dooley KJ, Blount RL. Internalizing symptoms and functional disability in children with noncardiac chest pain and innocent heart murmurs. Journal of Pediatric Psychology. 38: 255-64. PMID 23132933 DOI: 10.1093/jpepsy/jss111  0.011
2013 Boutte GS, Johnson GL. Do Educators See and Honor Biliteracy and Bidialectalism in African American Language Speakers? Apprehensions and Reflections of Two Grandparents/Professional Educators Early Childhood Education Journal. 41: 133-141. DOI: 10.1007/s10643-012-0538-5  0.01
2017 Almeter PJ, Johnson GL, Schwieterman PA, Grantz DA, Pasala PP. Ambulatory care pharmacy: Realizing the potential for patient access and operational excellence. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 74: 1013-1019. PMID 28645999 DOI: 10.2146/ajhp160802  0.01
2023 French SM, Johnson G, May H. Examination of Dealloying in a Domestic Water Fitting Using Light Optical/Scanning Electron Microscopy and Raman Spectroscopy. Microscopy and Microanalysis : the Official Journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada. 29: 152. PMID 37613153 DOI: 10.1093/micmic/ozad067.069  0.01
2018 Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ. Best practices for implementing venous thromboembolism prophylaxis across the continuum of care. The American Journal of Managed Care. 24: S483-S488. PMID 30452200  0.01
2016 Johnson G. Trauma Triage and Trauma System Performance. The Western Journal of Emergency Medicine. 17: 331-2. PMID 27330666 DOI: 10.5811/westjem.2016.2.29900  0.01
2015 Montpellier E, Johnson GL, Faleh OA, Gigantino J, Kidane A, Chandolias N, Rawls C, Ingalls T, Sha XW. Suturing space: Tabletop portals for collaboration Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 9170: 472-484. DOI: 10.1007/978-3-319-20916-6_44  0.01
2013 Johnson GL. Theoretical considerations The Overproduction Trap in U.S. Agriculture: a Study of Resource Allocation From World War I to the Late 1960s. 5: 22-40. DOI: 10.4324/9781315064017  0.01
2013 Boutte GS, Johnson GL. Funga Alafia 1: Toward Welcoming, Understanding, and Respecting African American Speakers' Bilingualism and Biliteracy Equity and Excellence in Education. 46: 300-314. DOI: 10.1080/10665684.2013.806850  0.01
2012 Johnson GL. In reply American Family Physician. 86: 992-994.  0.01
2012 Dunmire T, Johnson GL. Pointed in the right direction Quality Progress. 45: 16-22.  0.01
2011 Tribble DA, Burnette R, Biller DM, Brookins L, Capps R, Choi MH, Choudhary KJ, Cohen SA, Cooley TW, Dabestani AT, De La Torre C, Dumitru D, Fortier C, Giacomelli B, Hermann S, ... Johnson GL, et al. ASHP statement on bar-code verification during inventory, preparation, and dispensing of medications American Journal of Health-System Pharmacy. 68: 442-445. PMID 21330687 DOI: 10.2146/sp100012  0.01
2009 Johnson GL. The future of iaea safety standards 6th American Nuclear Society International Topical Meeting On Nuclear Plant Instrumentation, Control, and Human-Machine Interface Technologies 2009. 3: 1834-1838.  0.01
2009 Johnson GL. Tinidazole (Tindamax) for trichomoniasis and bacterial vaginosis American Family Physician. 79: 102-104.  0.01
2008 Di Luzio M, Johnson GL, Daly C, Eischeid JK, Arnold JG. Constructing retrospective gridded daily precipitation and temperature datasets for the conterminous United States Journal of Applied Meteorology and Climatology. 47: 475-497. DOI: 10.1175/2007JAMC1356.1  0.01
2007 Dhanasekaran DN, Johnson GL. Guest editors Oncogene. 26: 3095-3096. DOI: 10.1038/sj.onc.1210393  0.01
2005 Johnson G. Five trends impacting hospitals' business processes and financial health. Health Management Technology. 26: 32, 34, 36. PMID 16259139  0.01
2005 Pickhardt PJ, Taylor AJ, Johnson GL, Fleming LA, Jones DA, Pfau PR, Reichelderfer M. Building a CT colonography program: necessary ingredients for reimbursement and clinical success. Radiology. 235: 17-20. PMID 15798164 DOI: 10.1148/radiol.2351041671  0.01
2005 Johnson GL. Busch's THE ECLIPSE OF MORALITY: SCIENCE, STATE AND MARKET Research in the History of Economic Thought and Methodology. 23: 209-227. DOI: 10.1016/S0743-4154(05)23012-2  0.01
2004 Sinyanskii AA, Melnikov SP, Dovbysh LE, Johnson GL. Nuclear-optical converters for neutron detection American Nuclear Society 4th International Topical Meeting On Nuclear Plant Instrumentation, Control and Human Machine Interface Technology. 969-975.  0.01
2004 Johnson GL, Brown J. Workforce planning not a common practice, IPMA-HR study finds Public Personnel Management. 33: 379-388.  0.01
2004 Johnson GL, Daly C. Bulletin of the American Meteorological Society: Foreword Bulletin of the American Meteorological Society. 4815.  0.01
Hide low-probability matches.